WO2014149139A2 - Halogenopyrazoles as inhibitors of thrombin - Google Patents

Abstract

There are provided inter alia multisubstituted aromatic compounds useful for the inhibition of thrombin, which compounds include substituted pyrazolyi. There are additionally provided pharmaceutical compositions. There are additionally provided methods of treating and preventing a disease or disorder, which disease or disorder is amenable to treatment or prevention by the inhibition of thrombin.

Description

HALOGENOPYRAZOLES AS INHIBITORS OF THROMBIN BACKGROUND OF THE INVENTION

[0001] The present disclosure relates to compounds, e.g., multisubstituted aromatic compounds, which exhibit biological activity, e.g., inhibitory action, against thrombin (activated blood-coagulation factor II; EC 3.4.21.5). [0002] In mammalian systems, blood vessel injuries result in bleeding events, which are dealt with by the blood coagulation cascade. The cascade includes the Extrinsic and Intrinsic pathways, involving the activation of at least 13 interconnected factors and a variety of co- factors and other regulatory proteins. Upon vascular injury, plasma factor VII interacts with exposed Tissue Factor (TF), and the resultant TF-fVIIa complex initiates a complex series of events. Factor fXa is produced directly 'downstream' from the TF-fVIIa complex, and amplified manifold via the Intrinsic Pathway. FXa then serves as the catalyst for formation of thrombin (flla), which in turn is the direct precursor to fibrinolysis. The outcome is a fibrinolytic clot, which stops the bleeding. Fibrinolysis of the polymeric clot into fibrin monomers leads to dissolution and a return of the system to the pre-clot state. The cascade is a complex balance of factors and co- factors and is tightly regulated.

[0003] In disease states, undesired up- or down-regulation of any factor leads to conditions such as bleeding or thrombosis. Historically, anticoagulants have been used in patients at risk of suffering from thrombotic complications, such as angina, stroke and heart attack.

[0004] Warfarin has enjoyed dominance as a first-in-line anticoagulant therapeutic.

Developed in the 1940s, it is a Vitamin K antagonist and inhibits factors II, VII, IX and X, amongst others. It is administered orally, but its ease of use is tempered by other effects: it has a very long half life (>2 days) and has serious drug-drug interactions. Importantly, since Vitamin K is a ubiquitous cofactor within the coagulation cascade, antagonism results in the simultaneous inhibition of many clotting factors and thus can lead to significant bleeding complications.

[0005] Much attention has been focused on heparin, the naturally-occurring polysaccharide that activates AT III, the endogenous inhibitor of many of the factors in the coagulation cascade. The need for parenteral administration for the heparin-derived therapeutics, and the inconvenient requirements for close supervision for the orally available warfarin, has resulted in a drive to discover and develop orally available drugs with wide therapeutic windows for safety and efficacy. [0006] Indeed, the position of thrombin in the coagulation cascade has made it a popular target for drug discovery. Without wishing to be bound by any theory, it is believed that the ultimate development of direct thrombin inhibitors (DTls) is usefully based upon the classical D-Phe-Pro-Arg motif, a sequence that mimics fibrinogen, which is a natural substrate of thrombin. Without further wishing to be bound by any theory, it is believed that the use of DTls is very well precedented, such as with the hirudin-based anticoagulants, and thus there is strong interest in the discovery and development of novel DTls.

[0007] A thorough discussion of thrombin and its roles in the coagulation process can be found in a variety of references, including the following which are incorporated herein by reference in their entireties and for all purposes: Wieland, H. A., et al, 2003, Curr Opin Investig Drugs, 4:264-7 '1 ; Gross, P. L. & Weitz, J. I., 2008, Arterioscler Thromb Vase Biol, 28:380-6; Hirsh, J., et al, 2005, Blood, 105:453-63; Prezelj, A., et al, 2007, Curr Pharm Des, 13:287-312. BRIEF SUMMARY OF THE INVENTION

[0008] Embodiments of the invention encompass compounds with structure of Formula (la):

or pharmaceutically acceptable salt, ester, solvate, or prodrug thereof; wherein Ring A can be substituted or unsubstituted pyrazolyl; L¹ and L³ can be independently a bond, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, -S-, -SO-, -S0₂-, -0-, -NHS0₂-, or -NR⁴-; L² can be absent, a bond, substituted or unsubstituted alkylene, substituted or unsubstituted eteroalkylene, -S-, -SO-, -S0₂-, -0-, -NHS0₂-, or -NR⁴-; R¹ and R³ can be independently hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyi, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted heterocycloalkenyl, substituted or unsubstituted aryl, substituted or

unsubstituted fused ring aryl, or substituted or unsubstituted heteroaryl; R² can be absent, hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted

heteroalkyl, substituted or unsubstituted cycloalkyi, substituted or unsubstituted cycioalkenyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted heterocycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted fused ring aryl, or substituted or unsubstituted heteroaryl, provided that when L² can be absent, R² can be absent; R⁴ can be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkyi, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted cycioalkenyl, substituted or unsubstituted heterocycloalkenyl, and substituted or unsubstituted fused ring aryl or substituted or unsubstituted heteroaryl; and Y can be a halogen. In some embodiments of the methods, L and R² can be absent. In some embodiments, the compound can have the structure of Formula (Ila) or Formula (lib):

[0009] In some embodiments where the compound can have the structure of Formula (Ila),

3 3

L can be a bond, or substituted or unsubstituted alkylene, and R can be substituted or unsubstituted aryl, substituted or unsubstituted fused ring aryl, substituted or unsubstituted heterocycloalkyl, or substituted or unsubstituted heteroaryl, and Y can be fluorine. In some embodiments where the compound can have the structure of Formula (lla), L³ can be -C(0)0, R³ can be substituted or unsubstituted alkyl, and Y can be fluorine. In some embodiments where the compound can have the structure of Formula (Ila), L³ can be -C(0)NR⁵-, R⁵ can be hydrogen or alkyl, R can be substituted or unsubstituted alkyl, or substituted or unsubstituted aryl, and Y can be fluorine. In some embodiments, R³ can be substituted or unsubstituted phenyl. In some embodiments, the heteroaryl can be pyridyl, pyridazinyl, pyrimidinyl, thienyl, or furyl. In some embodiments, R³ can be chloro- substituted thienyl. In some embodiments, the heterocycloalkyl can be morpholinyl, oxanyl, or oxetanyl. In some embodiments, the fused ring aryl can be benzodioxinyl or naphthyl. In some embodiments, L¹ can be a bond, -S-, -NR⁴-, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene, and R¹ can be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted fused ring 91 aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl.

92 In some embodiments, the heteroaryl can be pyridyl, pyridazinyl, pyrimidinyl, thienyl, or

93 furyl. In some embodiments, R¹ can be chloro-substituted thienyl. In some embodiments, the

94 heterocycloalkyl can be morpholinyl, oxanyl, or oxetanyl. In some embodiments, the fused

95 ring aryl can be benzodioxinyl or naphthyl. In some embodiments, R¹ can be substituted or

96 unsubstituted phenyl. In some embodiments, L² can be a bond, and R² can be hydrogen. In

97 some embodiments, L can be substituted or unsubstituted alkylene or -C(O)-, and R can be

98 hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl,

99 substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted

100 or unsubstituted heterocycloalkyl, substituted or unsubstituted heterocycloalkenyl, substituted

101 or unsubstituted aryl, substituted or unsubstituted fused ring aryl, or substituted or

102 unsubstituted heteroaryl. In some embodiments, the heteroaryl can be pyridyl, pyridazinyl,

103 pyrimidinyl, thienyl, or furyl. In some embodiments, R² can be substituted or unsubstituted

104 alkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted

105 heterocycloalkyl. In some embodiments, the heterocycloalkyl can be morpholinyl, oxanyl, or

106 oxetanyl. In some embodiments, the fused ring aryl can be benzodioxinyl or naphthyl. In

107 some embodiments, R² can be substituted or unsubstituted phenyl.

108 [0010] In some embodiments where the compound can have the structure of Formula (lib),

109 L³ can be a bond, or substituted or unsubstituted alkylene, R³ can be substituted or

1 10 unsubstituted aryl, substituted or unsubstituted fused ring aryl, substituted or unsubstituted

1 1 1 heterocycloalkyl, or substituted or unsubstituted heteroaryl, and Y can be fluorine. In some

1 12 embodiments where the compound can have the structure of Formula (Ila), L³ can be

1 13 -C(0)0-, R³ can be substituted or unsubstituted alkyl, and Y can be fluorine. In some

1 14 embodiments where the compound can have the structure of Formula (Ila), L³ can be

1 15 -C(0)NR⁵-, R⁵ can be hydrogen or alkyl, R can be substituted or unsubstituted alkyl, or

1 16 substituted or unsubstituted aryl, and Y can be fluorine. In some embodiments, R³ can be

1 17 substituted or unsubstituted phenyl. In some embodiments, the heteroaryl can be pyridyl,

1 18 pyridazinyl, pyrimidinyl, thienyl, or furyl. In some embodiments, R³ can be chloro-

1 19 substituted thienyl. In some embodiments, the heterocycloalkyl can be morpholinyl, oxanyl,

120 or oxetanyl. In some embodiments, the fused ring aryl can be benzodioxinyl or naphthyl. In

121 some embodiments, L¹ can be a bond, -S-, -NR⁴-, substituted or unsubstituted alkylene, or

122 substituted or unsubstituted heteroalkylene, and R¹ can be hydrogen, substituted or

123 unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted fused ring

124 aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl. 125 In some embodiments, the heteroaryl can be pyridyl, pyridazinyl, pyrimidinyl, thienyl, or

126 furyl. In some embodiments, R¹ can be chloro-substituted thienyl. In some embodiments, the

127 heterocycloalkyl can be morpholinyl, oxanyl, or oxetanyl. In some embodiments, the fused

128 ring aryl can be benzodioxinyl or naphthyl. In some embodiments, R¹ can be substituted or

129 unsubstituted phenyl. In some embodiments, L² can be a bond, and R² can be hydrogen. In

2 2

130 some embodiments, L can be substituted or unsubstituted alkylene or -C(O)-, and R can be

131 hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl,

132 substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted

133 or unsubstituted heterocycloalkyl, substituted or unsubstituted heterocycloalkenyl, substituted

134 or unsubstituted aryl, substituted or unsubstituted fused ring aryl, or substituted or

135 unsubstituted heteroaryl. In some embodiments, the heteroaryl can be pyridyl, pyridazinyl,

136 pyrimidinyl, thienyl, or furyl. In some embodiments, R² can be substituted or unsubstituted

137 alkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted

138 heterocycloalkyl. In some embodiments, the heterocycloalkyl can be morpholinyl, oxanyl, or

139 oxetanyl. In some embodiments, the fused ring aryl can be benzodioxinyl or naphthyl. In

140 some embodiments, R² can be substituted or unsubstituted phenyl. In some embodiments, the

141 compound can be selected from those set forth in Table A.

142 [0011] Embodiments of the invention also encompass pharmaceutical compositions

143 including such compounds, or a compound as set forth in Table A, and a pharmaceutically

144 acceptable excipient. Embodiments of the invention also encompass methods for treating a

145 disease or disorder in a subject, including administering such compounds or pharmaceutical

146 compositions to a subject in need thereof in an amount effective to treat said disease or

147 disorder. In some embodiments, the disease or disorder is a thrombotic disorder. In some

148 embodiments, the thrombotic disorder is acute coronary syndrome, venous

149 thromboembolism, arterial thromboembolism or cardiogenic thromboembolism. In some 50 embodiments, the disease or disorder is fibrosis. In some embodiments, the disease or 51 disorder is Alzheimer's Disease. In some embodiments, the disease or disorder is multiple 52 sclerosis. In some embodiments, the disease or disorder is pain. In some embodiments, the 53 disease or disorder is cancer. Embodiments of the invention also encompass methods for 54 preventing a disease or disorder in a subject, including administering such compounds or 55 pharmaceutical compositions to a subject in need thereof in an amount effective to prevent 56 said disease or disorder. In some embodiments, the disease or disorder can be a thrombotic 57 disorder. In some embodiments, the thrombotic disorder can be acute coronary syndrome, 58 venous thromboembolism, arterial thromboembolism or cardiogenic thromboembolism. In 159 some embodiments, the thrombotic disorder can be disseminated intravascular coagulation. In

160 some embodiments, the thrombotic disorder involves the presence or the potential formation

161 of a blood clot thrombus.

162 BRIEF DESCRIPTION OF THE DRAWINGS

163 [0012] Not applicable.

164 DETAILED DESCRIPTION OF THE INVENTION

165 I. Definitions

166 [0013] The abbreviations used herein have their conventional meaning within the chemical

167 and biological arts. The chemical structures and formulae set forth herein are constructed

168 according to the standard rules of chemical valency known in the chemical arts.

169 [0014] Where substituent groups are specified by their conventional chemical formulae,

170 written from left to right, they equally encompass the chemically identical substituents that

171 would result from writing the structure from right to left, e.g., -CH₂0- is equivalent to

172 -OCH2-.

173 [0015] As used herein, the term "attached" signifies a stable covalent bond, certain

174 preferred points of attachment being apparent to those of ordinary skill in the art.

175 [0016] The terms "halogen" or "halo" include fluorine, chlorine, bromine, and iodine.

176 Additionally, terms such as "haloalkyl" are meant to include monohaloalkyl and

177 polyhaloalkyl. For example, the term "halo(Ci-C4)alkyl" includes, but is not limited to,

178 fluoromethyl, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-

179 bromopropyl, and the like.

180 [0017] The term "alkyl," by itself or as part of another substituent, means, unless otherwise

181 stated, a straight (i.e., unbranched) or branched chain, or combination thereof, which can be

182 fully saturated, mono- or polyunsaturated and can include di- and multivalent radicals, having

183 the number of carbon atoms designated (i.e., C]-Cio means one to ten carbons). Examples of

184 saturated hydrocarbon radicals include, but are not limited to, groups such as methyl, ethyl, n-

185 propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, (cyclohexyl)methyl, homologs and

186 isomers of, for example, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like. An unsaturated

187 alkyl group is one having one or more double bonds or triple bonds. Examples of unsaturated

188 alkyl groups include, but are not limited to, vinyl, 2-propenyl, crotyl, 2-isopentenyl, 2-

189 (butadienyl), 2,4-pentadienyl, 3-(l ,4-pentadienyl), ethynyl, 1 - and 3-propynyl, 3-butynyl, and 190 the higher homologs and isomers. Accordingly, the term "alkyl" can refer to Q-C16 straight

191 chain saturated, Q-Cie branched saturated, C3-C8 cyclic saturated and Q-C16 straight chain or

192 branched saturated aliphatic hydrocarbon groups substituted with C3-C8 cyclic saturated

193 aliphatic hydrocarbon groups having the specified number of carbon atoms. For example,

194 this definition shall include but is not limited to methyl (Me), ethyl (Et), propyl (Pr), butyl

195 (Bu), pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, isopropyl (i-Pr), isobutyl (i-Bu), tert-

196 butyl (t-Bu), sec-butyl (s-Bu), isopentyl, neopentyl, cyclopropyl, cyclobutyl, cyclopentyl,

197 cyclohexyl, cycloheptyl, cyclooctyl, cyclopropylmethyl, and the like.

198 [0018] The term "alkylene," by itself or as part of another substituent, means, unless

199 otherwise stated, a divalent radical derived from an alkyl, as exemplified, but not limited by,

200 -CH2CH2CH2CH2-. Typically, an alkyl (or alkylene) group will have from 1 to 24 carbon

201 atoms, with those groups having 10 or fewer carbon atoms being preferred in the compounds

202 disclosed herein. A "lower alkyl" or "lower alkylene" is a shorter chain alkyl or alkylene

203 group, generally having eight or fewer carbon atoms.

204 [0019] The term "heteroalkyl," by itself or in combination with another term, means, unless

205 otherwise stated, a stable straight or branched chain, or combinations thereof, consisting of at

206 least one carbon atom and at least one heteroatom selected from the group consisting of O, N,

207 P, Si, and S, and wherein the nitrogen and sulfur atoms can optionally be oxidized, and the

208 nitrogen heteroatom can optionally be quaternized. The heteroatom(s) O, N, P, S, and Si can

209 be placed at any interior position of the heteroalkyl group or at the position at which the alkyl

210 group is attached to the remainder of the molecule. Examples include, but are not limited to:

211 -CH2-CH2-O-CH3, -CH2-CH2-NH-CH3, -CH₂-CH2-N(CH₃)-CH₃, -CH₂-S-CH₂-CH₃,

212 -CH2-CH2, -S(0)-CH₃, -CH2-CH₂-S(0)2-CH₃, -CH=CH-0-CH₃, -Si(CH₃)₃,

213 -CH₂-CH=N-OCH₃, -CH=CH-N(CH₃)-CH₃, -O-CH3, -O-CH2-CH3, and -CN. Up to two

214 heteroatoms can be consecutive, such as, for example, -CH2-NH-OCH3.

215 [0020] Similarly, the term "heteroalkylene," by itself or as part of another substituent, means,

216 unless otherwise stated, a divalent radical derived from heteroalkyl, as exemplified, but not

217 limited by, -CH2-CH2-S-CH2-CH2- and -CH2-S-CH2-CH2-NH-CH2-. For heteroalkylene

218 groups, heteroatoms can also occupy either or both of the chain termini (e.g., alkyleneoxy,

219 alkylenedioxy, alkyleneamino, alkylenediamino, and the like). Still further, for alkylene and

220 heteroalkylene linking groups, no orientation of the linking group is implied by the direction

221 in which the formula of the linking group is written. For example, the formula -C(0)2R'-

222 represents both -C(0)2R'- and -R'C(0)2-. As described above, heteroalkyl groups, as used 223 herein, include those groups that are attached to the remainder of the molecule through a

224 heteroatom, such as -C(0)R', -C(0)NR', -NR'R", -OR', -SR', and/or -S0₂R'. Where

225 "heteroalkyl" is recited, followed by recitations of specific heteroalkyl groups, such as

226 -NR'R" or the like, it will be understood that the terms heteroalkyl and -NR'R" are not

227 redundant or mutually exclusive. Rather, the specific heteroalkyl groups are recited to add

228 clarity. Thus, the term "heteroalkyl" should not be interpreted herein as excluding specific

229 heteroalkyl groups, such as -NR'R" or the like.

230 [0021] The terms "cycloalkyl" and "heterocycloalkyl," by themselves or in combination with

231 other terms, mean, unless otherwise stated, cyclic versions of "alkyl" and "heteroalkyl,"

232 respectively. Additionally, for heterocycloalkyl, a heteroatom can occupy the position at

233 which the heterocycle is attached to the remainder of the molecule. Examples of cycloalkyl

234 include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 1 -

235 cyclohexenyl, 3-cyclohexenyl, cycloheptyl, and the like. Examples of heterocycloalkyl

236 include, but are not limited to, l -(l ,2,5,6-tetrahydropyridyl), 1-piperidinyl, 2-piperidinyl, 3-

237 piperidinyl, 4-morpholinyl, 3-morpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl,

238 tetrahydrothien-2-yl, tetrahydrothien-3-yl, 1 -piperazinyl, 2-piperazinyl, and the like. A

239 "cycloalkylene" and a "heterocycloalkylene," alone or as part of another substituent, means a

240 divalent radical derived from a cycloalkyl and heterocycloalkyl, respectively.

241 [0022] The term "alkenyl" includes C₂-Ci₆ straight chain unsaturated, C₂-Cn branched

242 unsaturated, Cs-Cg unsaturated cyclic, and C₂-Ci6 straight chain or branched unsaturated

243 aliphatic hydrocarbon groups substituted with C3-C8 cyclic saturated and unsaturated

244 aliphatic hydrocarbon groups having the specified number of carbon atoms. Double bonds

245 can occur in any stable point along the chain and the carbon-carbon double bonds can have

246 either the cis or trans configuration. For example, this definition shall include but is not

247 limited to ethenyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl, decenyl,

248 undecenyl, 1 ,5-octadienyl, 1 ,4,7-nonatrienyl, cyclopentenyl, cyclohexenyl, cycloheptenyl,

249 cyclooctenyl, ethylcyclohexenyl, butenylcyclopentyl, l-pentenyl-3-cyclohexenyl, and the like.

250 Similarly, "heteroalkenyl" refers to heteroalkyl having one or more double bonds.

251 [0023] The term "alkynyl" refers in the customary sense to alkyl additionally having one or

252 more triple bonds. The term "cycloalkenyl" refers to cycloalkyl additionally having one or

253 more double bonds. The term "heterocycloalkenyl" refers to heterocycloalkyl additionally

254 having one or more double bonds. 255 [0024] The term "acyl" means, unless otherwise stated, -C(0)R where R is a substituted or

256 unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted

257 heteroalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or

258 substituted or unsubstituted heteroaryl.

259 [0025] Each of the above terms (e.g., "alkyl," "heteroalkyl," "aryl," and "heteroaryl")

260 includes both substituted and unsubstituted forms of the indicated radical. Preferred

261 substituents for each type of radical are provided herein.

262 [0026] Substituents for the alkyl and heteroalkyl radicals (including those groups often

263 referred to as alkylene, alkenyl, heteroalkylene, heteroalkenyl, alkynyl, cycloalkyl,

264 heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl) can be one or more of a variety of

265 groups selected from, but not limited to, -OR', =0, =NR', =N-OR', -NR'R", -SR', -halogen,

266 -SiR'R"R"', -OC(0)R', -C(0)R', -C0₂R', -CONR'R", -OC(0)NR'R", -NR"C(0)R',

267 -NR'-C(0)NR"R"', -NR"C(0)₂R', -NR-C(NR'R")=NR'", -S(0)R', -S(0)₂R', -S(0)₂NR'R",

268 -NRS0₂R', -CN, and -N0₂ in a number ranging from zero to (2m'+l ), where m' is the total

269 number of carbon atoms in such radical. R', R", and R'" each preferably independently refer

270 to hydrogen, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl,

271 substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl (e.g., aryl

272 substituted with 1 -3 halogens), substituted or unsubstituted alkyl, alkoxy, or thioalkoxy

273 groups, or arylalkyl groups. When a compound disclosed herein includes more than one R

274 group, for example, each of the R groups is independently selected as are each R', R", and R'"

275 group when more than one of these groups is present. When R' and R" are attached to the

276 same nitrogen atom, they can be combined with the nitrogen atom to form a 4-, 5-, 6-, or 7-

277 membered ring. For example, -NR'R" includes, but is not limited to, 1 -pyrrolidinyl and 4-

278 morpholinyl. From the above discussion of substituents, one of skill in the art will

279 understand that the term "alkyl" is meant to include groups including carbon atoms bound to

280 groups other than hydrogen groups, such as haloalkyl (e.g., -CF₃ and -CH₂CF₃) and acyl (e.g.,

281 -C(0)CH₃, -C(0)CF₃, -C(0)CH₂OCH₃, and the like).

282 [0027] Similar to the substituents described for the alkyl radical, substituents for the aryl

283 and heteroaryl groups are varied and are selected from, for example: -OR', -NR'R", -SR',

284 -halogen, -SiR'R"R"', -OC(0)R', -C(0)R', -C0₂R', -CONR'R", -OC(0)NR'R", -NR"C(0)R',

285 -NR'-C(0)NR"R"', -NR"C(0)₂R', -NR-C(NR'R")=NR'", -S(0)R', -S(0)₂R', -S(0)₂NR'R",

286 -NRS0₂R', -CN, -N0₂, -R', -N₃, -CH(Ph)₂, fluoro(CrC₄)alkoxy, and fluoro(d-C₄)alkyl, in a

287 number ranging from zero to the total number of open valences on the aromatic ring system; 288 and where R', R", and R'" are preferably independently selected from hydrogen, substituted or

289 unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted

290 cycloalkyi, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl,

291 and substituted or unsubstituted heteroaryl. When a compound disclosed herein includes

292 more than one R group, for example, each of the R groups is independently selected as are

293 each R', R", and R'" groups when more than one of these groups is present.

294 [0028] Two or more substituents can optionally be joined to form aryl, heteroaryl, cycloalkyi,

295 or heterocycloalkyl groups. Such so-called ring-forming substituents are typically, though

296 not necessarily, found attached to a cyclic base structure. In one embodiment, the ring-

297 forming substituents are attached to adjacent members of the base structure. For example,

298 two ring-forming substituents attached to adjacent members of a cyclic base structure create a

299 fused ring structure. In another embodiment, the ring-forming substituents are attached to a

300 single member of the base structure. For example, two ring-forming substituents attached to

301 a single member of a cyclic base structure create a spirocyclic structure. In yet another

302 embodiment, the ring-forming substituents are attached to non-adjacent members of the base

303 structure.

304 [0029] Two of the substituents on adjacent atoms of the aryl or heteroaryl ring can optionally

305 form a ring of the formula -T-C(0)-(CRR')_q-U-, wherein T and U are independently -NR-,

306 -0-, -CRR'-, or a single bond, and q is an integer of from 0 to 3. Alternatively, two of the

307 substituents on adjacent atoms of the aryl or heteroaryl ring can optionally be replaced with a

308 substituent of the formula -A-(CH2)_r-B-, wherein A and B are independently -CRR'-, -0-,

309 -NR-, -S-, -S(O) -, -S(0)₂-, -S(0)₂NR'-, or a single bond, and r is an integer of from 1 to 4.

310 One of the single bonds of the new ring so formed can optionally be replaced with a double

31 1 bond. Alternatively, two of the substituents on adjacent atoms of the aryl or heteroaryl ring

312 can optionally be replaced with a substituent of the formula -(CRR')_S-X'- (C"R"')_d-, where s

313 and d are independently integers of from 0 to 3, and X' is -0-, -NR'-, -S-, -S(O)-, -S(0)₂-, or

314 -S(0)₂NR'-. The substituents R, R, R", and R" are preferably independently selected from

315 hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyi,

316 substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and

317 substituted or unsubstituted heteroaryl.

318 [0030] As used herein, the terms "heteroatom" or "ring heteroatom" are meant to include

319 oxygen (O), nitrogen (N), sulfur (S), phosphorus (P), and silicon (Si). 320 [0031] The term "alkyloxy" (e.g. methoxy, ethoxy, propyloxy, allyloxy, cyclohexyloxy)

321 represents an alkyl group as defined above having the indicated number of carbon atoms

322 attached through an oxygen bridge (-0-).

323 [0032] The term "alkylthio" (e.g. methylthio, ethylthio, propylthio, cyclohexylthio and the

324 like) represents an alkyl group as defined above having the indicated number of carbon atoms

325 attached through a sulfur bridge (-S-).

326 [0033] The term "alkylamino" represents one or two alkyl groups as defined above having

327 the indicated number of carbon atoms attached through an amine bridge. The two alkyl

328 groups canbe taken together with the nitrogen to which they are attached forming a cyclic

329 system containing 3 to 8 carbon atoms with or without one Ci-Ci6alkyl, arylCo-Ci6alkyl, or

330 Co-Ci₆alkylaryl substituent.

331 [0034] The term "alkylaminoalkyl" represents an alkylamino group attached through an

332 alkyl group as defined above having the indicated number of carbon atoms.

333 [0035] The term "alkyloxy(alkyl)amino" (e.g. methoxy(methyl)amine,

334 ethoxy(propyl)amine) represents an alkyloxy group as defined above attached through an

335 amino group, the amino group itself having an alkyl substituent.

336 [0036] The term "alkylcarbonyl" (e.g. cyclooctylcarbonyl, pentylcarbonyl, 3-

337 hexylcarbonyl) represents an alkyl group as defined above having the indicated number of

338 carbon atoms attached through a carbonyl group.

339 [0037] The term "alkylcarboxy" (e.g. heptylcarboxy, cyclopropylcarboxy, 3-

340 pentenylcarboxy) represents an alkylcarbonyl group as defined above wherein the carbonyl is

341 in turn attached through an oxygen.

342 [0038] The term "alkylcarboxyalkyl" represents an alkylcarboxy group attached through an

343 alkyl group as defined above having the indicated number of carbon atoms.

344 [0039] The term "alkylcarbonylamino" (e.g. hexylcarbonylamino,

345 cyclopentylcarbonylaminomethyl, methylcarbonylaminophenyl) represents an alkylcarbonyl

346 group as defined above wherein the carbonyl is in turn attached through the nitrogen atom of

347 an amino group.

348 [0040] The nitrogen group can itself be substituted with an alkyl or aryl group.

349 [0041] The term "aryl" means, unless otherwise stated, a polyunsaturated, aromatic,

350 hydrocarbon substituent, which can be a single ring or multiple rings (preferably from 1 to 3

351 rings) that are fused together (i.e., a fused ring aryl) or linked covalently. A fused ring aryl 352 refers to multiple rings fused together wherein at least one of the fused rings is an aryl ring.

353 The term "heteroaryl" refers to aryl groups (or rings) that contain from one to four

354 heteroatoms selected from N, O, and S, wherein the nitrogen and sulfur atoms are optionally

355 oxidized, and the nitrogen atom(s) are optionally quaternized. Thus, the term "heteroaryl"

356 includes fused ring heteroaryl groups (i.e., multiple rings fused together wherein at least one

357 of the fused rings is a heteroaromatic ring). A 5,6-fused ring heteroarylene refers to two rings

358 fused together, wherein one ring has 5 members and the other ring has 6 members, and

359 wherein at least one ring is a heteroaryl ring. Likewise, a 6,6-fused ring heteroarylene refers

360 to two rings fused together, wherein one ring has 6 members and the other ring has 6

361 members, and wherein at least one ring is a heteroaryl ring. And a 6,5-fused ring

362 heteroarylene refers to two rings fused together, wherein one ring has 6 members and the

363 other ring has 5 members, and wherein at least one ring is a heteroaryl ring. A heteroaryl

364 group can be attached to the remainder of the molecule through a carbon or heteroatom.

365 Non-limiting examples of aryl and heteroaryl groups include phenyl, 1-naphthyl, 2-naphthyl,

366 4-biphenyl, 1 -pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl,

367 pyrazinyl, 2-oxazolyl, 4-oxazolyl, 2-phenyl-4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-

368 isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl,

369 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-benzothiazolyl,

370 purinyl, 2-benzimidazolyl, 5-indolyl, 1-isoquinolyl, 5-isoquinolyl, 2-quinoxalinyl, 5-

371 quinoxalinyl, 3-quinolyl, and 6-quinolyl. Substituents for each of the above noted aryl and

372 heteroaryl ring systems are selected from the group of acceptable substituents described

373 below. An "arylene" and a "heteroarylene," alone or as part of another substituent, mean a

374 divalent radical derived from an aryl and heteroaryl, respectively. Accordingly, the term

375 "aryl" can represent an unsubstituted, mono-, di- or trisubstituted monocyclic, polycyclic,

376 biaryl and heterocyclic aromatic groups covalently attached at any ring position capable of

377 forming a stable covalent bond, certain preferred points of attachment being apparent to those

378 skilled in the art (e. g. 3-indolyl, 4-imidazolyl). The aryl substituents are independently

379 selected from the group consisting of halo, nitro, cyano, trihalomethyl, Ci-iealkyl, arylQ.

380 _lealkyl, Co-i6alkyloxyC₀-i6alkyl, arylCo-i6alkyloxyCo-i6alkyl, Co-i6alkylthioC₀-i6alkyl,

381 arylCo-i6alkylthioCo-i6alkyl, Co-i6alkylaminoCo-i6alkyl, arylCo-i6alkylaminoC₀-i6alkyl,

382 di(arylCi-i6alkyl)aminoC₀-i₆alkyl, Ci-i₆alkylcarbonylC₀-i6alkyl, arylCi.i6alkylcarbonylCo-

383 lealkyl, Ci-i₆alkylcarboxyCo-i6alkyl, arylCi-i₆alkylcarboxyCo-i6alkyl, Ci.

384 i6alkylcarbonylaminoCo-i6alkyl, arylCi-i₆alkylcarbonylaminoCo-i6alkyl,-Co-i6alkylCOOR4, -

385 Co-i6alkylCONR₅Rs wherein R4, Rs and R6 are independently selected from hydrogen, Q- 386 Ci ialkyl, arylCo-Ci ialkyl, or R5 and Re are taken together with the nitrogen to which they are

387 attached forming a cyclic system containing 3 to 8 carbon atoms with or without one Q.

388 _]6alkyl, arylCo-Ci6alkyl, or Q)-CIi6alkylaryl substituent. Aryl includes but is not limited to

389 pyrazolyl and triazolyl.

390 [0042] For brevity, the term "aryl" when used in combination with other terms (e.g., aryloxy,

391 arylthioxy, arylalkyl) includes both aryl and heteroaryl rings as defined above. Thus, the

392 terms "arylalkyl," "aralkyl" and the like are meant to include those radicals in which an aryl

393 group is attached to an alkyl group (e.g., benzyl, phenethyl, pyridylmethyl, and the like)

394 including those alkyl groups in which a carbon atom (e.g., a methylene group) has been

395 replaced by, for example, an oxygen atom (e.g., phenoxymethyl, 2-pyridyloxymethyl, 3-(l -

396 naphthyloxy)propyl, and the like), or a sulfur atom. Accordingly, the terms "arylalkyl" and

397 the like (e.g. (4-hydroxyphenyl)ethyl, (2-aminonaphthyl)hexyl, pyridylcyclopentyl)

398 represents an aryl group as defined above attached through an alkyl group as defined above

399 having the indicated number of carbon atoms.

400 [0043] The term "oxo," as used herein, means an oxygen that is double bonded to a carbon

401 atom.

402 [0044] The term "alkylsulfonyl," as used herein, means a moiety having the formula

403 -S(0₂)-R', where R' is an alkyl group as defined above. R' can have a specified number of

404 carbons (e.g., "C1-C4 alkylsulfonyl").

405 [0045] The term "carbonyloxy" represents a carbonyl group attached through an oxygen

406 bridge.

407 [0046] In the above definitions, the terms "alkyl" and "alkenyl" can be used

408 interchangeably in so far as a stable chemical entity is formed, as would be apparent to those

409 skilled in the art.

410 [0047] The term "linker" refers to attachment groups interposed between substituents, e.g.,

411 R¹, R² or R³ described herein, e.g., Formula (la) and generically referred to as Rⁿ, and the

412 group which is substituted, e.g., "ring A" group of e.g., Formula (la). In some embodiments,

413 the linker includes amido (-CONH-R" or -NHCO-R"), thioamido (-CSNH-R" or -NHCS-R"),

414 carboxy 1 (-C0₂-Rⁿ or -OCOR"), carbonyl (-CO-R"), urea (-NHCONH-R"), thiourea

415 (-NHCSNH-R"), sulfonamido (-NHS0₂-Rⁿ or -S0₂NH-Rⁿ), ether (-0-R"), sulfonyl

416 (-S0₂-Rⁿ), sulfoxyl (-SO-R"), carbamoyl (-NHC0₂-Rⁿ or -OCONH-R"), or amino (-NHR")

417 linking moieties. 418 [0048] A "substituent group," as used herein, means a group selected from the following

419 moieties:

420 (A) -OH, -NH₂, -SH, -CN, -CF₃, -N0₂, oxo, halogen, -COOH, unsubstituted alkyl,

421 unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl,

422 unsubstituted aryl, unsubstituted heteroaryl, and

423 (B) alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, substituted with

424 at least one substituent selected from:

425 (i) oxo, -OH, -NH₂, -SH, -CN, -CF₃, -N0₂, halogen, -COOH, unsubstituted alkyl,

426 unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl,

427 unsubstituted aryl, unsubstituted heteroaryl, and

428 (ii) alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, substituted

429 with at least one substituent selected from:

430 (a) oxo, -OH, -NH₂, -SH, -CN, -CF₃, -N0₂, halogen, -COOH, unsubstituted alkyl,

431 unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted

432 heterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl, and

433 (b) alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, substituted

434 with at least one substituent selected from: oxo, -OH, -NH₂, -SH, -CN, -CF₃,

435 -N0₂, halogen, -COOH, unsubstituted alkyl, unsubstituted heteroalkyl,

436 unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, and

437 unsubstituted heteroaryl.

438 [0049] A "size-limited substituent" or " size-limited substituent group," as used herein,

439 means a group selected from all of the substituents described above for a "substituent group,"

440 wherein each substituted or unsubstituted alkyl is a substituted or unsubstituted C1-C20 alkyl,

441 each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 20

442 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or

443 unsubstituted C4-C₈ cycloalkyl, and each substituted or unsubstituted heterocycloalkyl is a

444 substituted or unsubstituted 4 to 8 membered heterocycloalkyl.

445 [0050] A "lower substituent" or " lower substituent group," as used herein, means a group

446 selected from all of the substituents described above for a "substituent group," wherein each

447 substituted or unsubstituted alkyl is a substituted or unsubstituted Ci-C₈ alkyl, each

448 substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 8 membered

449 heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C5-

450 C₇ cycloalkyl, and each substituted or unsubstituted heterocycloalkyl is a substituted or

451 unsubstituted 5 to 7 membered heterocycloalkyl. 452 [0051] The term "about" used in the context of a numeric value indicates a range of +/-

453 10% of the numeric value, unless expressly indicated otherwise.

454 II. Compounds

455 [0052] In one aspect, there is provided a compound with structure of Formula (la):

456

ia)

457 or pharmaceutically acceptable salt, ester, solvate, or prodrug thereof. Ring A is substituted

458 or unsubsituted pyrazolyl. L¹ and L³ are independently a bond, substituted or unsubstituted

459 alkylene, substituted or unsubstituted heteroalkylene, -S-, -SO-, -S0₂-, -0-, -NHSO2-, or -

460 NR.⁴-. L² is absent, a bond, a hydrogen, substituted or unsubstituted alkylene, substituted or

461 unsubstituted heteroalkylene, -S-, -SO-, -S0₂-, -0-, -NHSO₂-, or -NR⁴-. R¹ and R³ are

462 independently hydrogen, halogen, substituted or unsubstituted alkyl, substituted or

463 unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted

464 cycloalkenyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted

465 heterocycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted fused ring

466 aryl,or substituted or unsubstituted heteroaryl. R² is absent, hydrogen, halogen, substituted or

467 unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted

468 cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted

469 heterocycloalkyl, substituted or unsubstituted heterocycloalkenyl, substituted or unsubstituted

470 aryl, substituted or unsubstituted fused ring aryl, or substituted or unsubstituted heteroaryl.

471 R⁴ is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl,

472 substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted

473 or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or

474 unsubstituted aryl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted

475 heterocycloalkenyl, substituted or unsubstituted fused ring aryl, or substituted or

476 unsubstituted heteroaryl. Y is a halogen. . In some embodiments, R² can be absent provided

477 L² is also absent.

478 [0053] In some embodiments, the compound is a pharmaceutically acceptable salt, ester,

479 solvate, or prodrug of a compound of Formula (Ia). In some embodiments, the compound is

480 not an ester, not a solvate, and not a prodrug. 481 [0054] Further to any embodiment above, in some embodiments L¹ is -S-, -NR⁴-,

482 substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene, where R⁴

483 is as described above in regards to formula la, and R¹ is hydrogen, substituted or

484 unsubstituted alkyl, substituted or unsubstituted aryl, substituted of unsubstituted fused ring

485 aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl.

486 In some embodiments, R³ is substituted or unsubstituted aryl. In some embodiments, R³ is

487 unsubstituted aryl. In some embodiments, R³ is unsubstituted phenyl. In some embodiments,

488 L² is a bond. In some embodiments, L² is a bond and R² is hydrogen. Y is fluorine.

2 2

489 [0055] Further to any embodiment above, in some embodiments L is -C(O)-, and R is

490 substituted or unsubstituted alkyl, hydrogen, substituted or unsubstituted heteroalkyl,

491 substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted

492 or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or

493 unsubstituted aryl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted

494 heterocycloalkenyl, substituted or unsubstituted fused ring aryl, or substituted or

495 unsubstituted heteroaryl. In some embodiments, R² is unsubstituted aryl. In some

496 embodiments, R² is unsubstituted phenyl.

497 [0056] In some embodiments, L² and R² are absent, providing a compound with structure

498 of Formula (lb) following.

500 [0057] In some embodiments, the compound is a pharmaceutically acceptable salt, ester,

501 solvate, or prodrug of a compound of Formula (lb). In some embodiments, the compound is

502 not an ester, not a solvate, and not a prodrug.

503 [0058] In some embodiments, there is provided a compound according to Formula (la) with

504 structure of either of Formulae (Ila) or (lib) following.

505

(lib) 506 [0059] In some embodiments, the compound has the structure of Formula (Ila). In some

507 embodiments, L³ is a bond, or substituted or unsubstituted alkylene, and R³ is substituted or

508 unsubstituted aryl, substituted or unsubstituted fused ring aryl, substituted or unsubstituted

3 ·

509 heterocycloalkyl, or substituted or unsubstituted heteroaryl. In some embodiments, R is

510 substituted or unsubstituted phenyl, or substituted or unsubstituted thienyl. In some

51 1 embodiments, R³ is unsubstituted phenyl. In some embodiments, R³ is unsubstituted thienyl.

512 In some embodiments, R 3 is a chloro-substituted thienyl. In some embodiments, R 3 i ·s

513 substituted or unsubstituted pyridyl, or substituted or unsubstituted pyridazinyl. In some

514 embodiments, R³ is unsubstituted pyridyl. In some embodiments, R³ is unsubstituted

515 pyridazinyl. In some embodiments, R³ is substituted or unsubstituted pyrimidinyl, or

516 substituted or unsubstituted furyl. In some embodiments, R³ is unsubstituted pyrimidinyl. In

517 some embodiments, R³ is unsubstituted furyl. In some embodiments, R³ is substituted or

518 unsubstituted morpholinyl, or substituted or unsubstituted oxanyl, or substituted or

519 unsubstituted oxetanyl. In some embodiments, R³ is unsubstituted morpholinyl. In some

520 embodiments, R³ is unsubstituted oxanyl. In some embodiments, R³ is unsubstituted

521 oxetanyl. In some embodiments, R³ is substituted or unsubstituted benzodioxinyl, or

22 substituted or unsubstituted naphthyl. In some embodiments, R³ is unsubstituted

23 benzodioxinyl. In some embodiments, R³ is unsubstituted naphthyl. In some embodiments, 24 R is substituted or unsubstituted phenyl. In some embodiments, Y is fluorine. 25 [0060] In some embodiments, the compound has the structure of Formula (Ila) wherein L³ 26 is -C(0)0-, and R³ is substituted or unsubstituted alkyl, and Y is fluorine. 27 [0061] In some embodiments, the compound has the structure of Formula (Ila) wherein L³ 28 is -C(0)NR⁵-, R⁵ is hydrogen or alkyl, and R³ is substituted or unsubstituted alkyl and Y is 29 fluorine. 30 [0062] Further to any embodiment above wherein the compound has the structure of 31 Formula (Ila), in some embodiments, L¹ is -S-, a bond, -NR⁴-, substituted or unsubstituted 32 alkylene, or substituted or unsubstituted heteroalkylene, where R⁴ is as described in formula 33 la and R¹ is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, 34 substituted or unsubstituted fused ring aryl, substituted or unsubstituted heteroaryl, or 35 substituted or unsubstituted heterocycloalkyl. In some embodiments, R¹ is a substituted or 36 unsubsituted pyridyl. In some embodiments, R¹ is a substituted or unsubsituted pyridazinyl. 37 In some embodiments, R¹ is a substituted or unsubsituted pyrimidinyl. In some embodiments, 38 R¹ is a substituted or unsubsituted thienyl. In some embodiments, R¹ is a substituted or 539 unsubsituted furyl. In some embodiments, R¹ is an unsubsituted pyridyl. In some

540 embodiments, R¹ is an unsubsituted pyridazinyl. In some embodiments, R¹ is an unsubsituted

541 pyrimidinyl. In some embodiments, R¹ is an unsubsituted thienyl. In some embodiments, R¹

542 is a chloro-substituted thienyl. In some embodiments, R¹ is an unsubsituted furyl. In some

543 embodiments, R¹ is a substituted or unsubsituted morpholinyl. In some embodiments, R¹ is a

544 substituted or unsubsituted oxanyl. In some embodiments, R¹ is a substituted or unsubsituted

545 oxetanyl. In some embodiments, R¹ is an unsubsituted morpholinyl. In some embodiments,

546 R¹ is an unsubsituted oxanyl. In some embodiments, R¹ is an unsubsituted oxetanyl. In some

547 embodiments, R¹ is substituted or unsubstituted benzodioxinyl. In some embodiments, R¹ is

548 substituted or unsubstituted naphthyl. In some embodiments, R¹ is unsubstituted

549 benzodioxinyl. In some embodiments, R¹ is unsubstituted naphthyl. In some embodiments,

550 R¹ is substituted or unsubstituted phenyl. In some embodiments, Y is fluorine.

551 [0063] Further to any embodiment above wherein the compound has the structure of

552 Formula (Ila), in some embodiments, L² is a bond. In some embodiments, R² is hydrogen. In

553 some embodiments, L² is substituted or unsubstituted alkylene or -C(O)-, and R² is

554 hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl,

555 substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted

556 or unsubstituted heterocycloalkyl, substituted or unsubstituted heterocycloalkenyl, substituted

557 or unsubstituted aryl, substituted or unsubstituted fused ring aryl, or substituted or

558 unsubstituted heteroaryl. In some embodiments, R² is a substituted or unsubsituted pyridyl. In

2 2

559 some embodiments, R is a substituted or unsubsituted pyridazinyl. In some embodiments, R

560 is a substituted or unsubsituted pyrimidinyl. In some embodiments, R² is a substituted or

561 unsubsituted thienyl. In some embodiments, R² is a substituted or unsubsituted furyl. In some

562 embodiments, R² is an unsubsituted pyridyl. In some embodiments, R² is an unsubsituted

563 pyridazinyl. In some embodiments, R² is an unsubsituted pyrimidinyl. In some embodiments,

564 R² is an unsubsituted thienyl. In some embodiments, R² is a chloro-substituted thienyl. In

565 some embodiments, R² is an unsubsituted furyl. In some embodiments, R² is a substituted or

566 unsubsituted morpholinyl. In some embodiments, R² is a substituted or unsubsituted oxanyl.

2 2

567 In some embodiments, R is a substituted or unsubsituted oxetanyl. In some embodiments, R

568 is an unsubsituted morpholinyl. In some embodiments, R² is an unsubsituted oxanyl. In some

569 embodiments, R² is an unsubsituted oxetanyl. In some embodiments, R² is substituted or

570 unsubstituted benzodioxinyl. In some embodiments, R² is substituted or unsubstituted

571 naphthyl. In some embodiments, R² is unsubstituted benzodioxinyl. In some embodiments, 2 2

R is unsubstituted naphthyl. In some embodiments, R is substituted or unsubstituted phenyl. In some embodiments, Y is fluorine. [0064] In some embodiments, the compound has the structure of Formula (lib). In some embodiments, L³ is a bond, or substituted or unsubstituted alkylene, and R³ is substituted or unsubstituted aryl, substituted or unsubstituted fused ring aryl, substituted or unsubstituted heterocycloalkyl, or substituted or unsubstituted heteroaryl. In some embodiments, R is substituted or unsubstituted phenyl, or substituted or unsubstituted thienyl. In some embodiments, R³ is unsubstituted phenyl. In some embodiments, R³ is unsubstituted thienyl. In some embodiments, R³ is a chloro-substituted thienyl. In some embodiments, R³ is substituted or unsubstituted pyridyl, or substituted or unsubstituted pyridazinyl. In some embodiments, R³ is unsubstituted pyridyl. In some embodiments, R³ is unsubstituted pyridazinyl. In some embodiments, R³ is substituted or unsubstituted pyrimidinyl, or substituted or unsubstituted furyl. In some embodiments, R³ is unsubstituted pyrimidinyl. In some embodiments, R³ is unsubstituted furyl. In some embodiments, R³ is substituted or unsubstituted morpholinyl, or substituted or unsubstituted oxanyl, or substituted or unsubstituted oxetanyl. In some embodiments, R is unsubstituted morpholinyl. In some embodiments, R³ is unsubstituted oxanyl. In some embodiments, R³ is unsubstituted oxetanyl. In some embodiments, R³ is substituted or unsubstituted benzodioxinyl, or substituted or unsubstituted naphthyl. In some embodiments, R³ is unsubstituted

benzodioxinyl. In some embodiments, R³ is unsubstituted naphthyl. In some embodiments, R³ is substituted or unsubstituted phenyl. In some embodiments, Y is fluorine. [0065] In some embodiments, the compound has the structure of Formula (lib) wherein L³ is -C(0)0-, and R³ is substituted or unsubstituted alkyl, and Y is fluorine. [0066] In some embodiments, the compound has the structure of Formula (lib) wherein L³ is -C(0)NR⁵-, R⁵ is hydrogen or alkyl, and R³ is substituted or unsubstituted alkyl and Y is fluorine. [0067] Further to any embodiment above wherein the compound has the structure of Formula (lib), in some embodiments, L¹ is a bond, -S-, -NR⁴-, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene, where R⁴ is as described in formula la and R¹ is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted fused ring aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl. In some embodiments, R¹ is a substituted or unsubsituted pyridyl. In some embodiments, R¹ is a substituted or unsubsituted pyridazinyl. 605 In some embodiments, R' is a substituted or unsubsituted pyrimidinyl. In some embodiments,

606 R¹ is a substituted or unsubsituted thienyl. In some embodiments, R¹ is a substituted or

607 unsubsituted furyl. In some embodiments, R¹ is an unsubsituted pyridyl. In some

608 embodiments, R¹ is an unsubsituted pyridazinyl. In some embodiments, R¹ is an unsubsituted

609 pyrimidinyl. In some embodiments, R¹ is an unsubsituted thienyl. In some embodiments, R¹

610 is a chloro-substituted thienyl. In some embodiments, R¹ is an unsubsituted furyl. In some

61 1 embodiments, R¹ is a substituted or unsubsituted morpholinyl. In some embodiments, R¹ is a

612 substituted or unsubsituted oxanyl. In some embodiments, R¹ is a substituted or unsubsituted

613 oxetanyl. In some embodiments, R¹ is an unsubsituted morpholinyl. In some embodiments,

614 R¹ is an unsubsituted oxanyl. In some embodiments, R¹ is an unsubsituted oxetanyl. In some

615 embodiments, R¹ is substituted or unsubstituted benzodioxinyl. In some embodiments, R¹ is

616 · substituted or unsubstituted naphthyl. In some embodiments, R¹ is unsubstituted

617 benzodioxinyl. In some embodiments, R¹ is unsubstituted naphthyl. In some embodiments,

618 R¹ is substituted or unsubstituted phenyl. In some embodiments, Y is fluorine.

619 [0068] Further to any embodiment above wherein the compound has the structure of

620 Formula (lib), in some embodiments, L² is a bond or substituted or unsubstituted alkylene. In

621 some embodiments, L² is a bond. In some embodiments, L² is unsubstituted alkylene. In

622 some embodiments, L² is substituted alkylene. In some embodiments, R² is hydrogen. In

623 some embodiments, R is substituted or unsubstituted alkyl, or substituted or unsubstituted

2 2

624 aryl. Further to any particular L , in some embodiments R is substituted or unsubstituted

625 alkyl, or substituted or unsubstituted aryl. In some embodiments, R² is unsubstituted alkyl.

626 In some embodiments, R² is unsubstituted aryl. In some embodiments, R³ is unsubstituted

627 phenyl. In some embodiments, R² is substituted alkyl. In some embodiments, R² is

628 substituted aryl. In some embodiments, Y is fluorine.

629 [0069] Further to any embodiment above wherein the compound has the structure of

630 Formula (lib), in some embodiments, L² is substituted or unsubstituted alkylene or -C(O)-,

631 and R² is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted

632 heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl,

633 substituted or unsubstituted heterocycloaikyl, substituted or unsubstituted heterocycloalkenyl,

634 substituted or unsubstituted aryl, substituted or unsubstituted fused ring aryl, or substituted or

635 unsubstituted heteroaryl. In some embodiments, R² is a substituted or unsubsituted pyridyl. In

636 some embodiments, R² is a substituted or unsubsituted pyridazinyl. In some embodiments, R²

637 is a substituted or unsubsituted pyrimidinyl. In some embodiments, R² is a substituted or

638 unsubsituted thienyl. In some embodiments, R² is a substituted or unsubsituted furyl. In some 639 embodiments, is an unsubsituted pyridyl. In some embodiments, is an unsubsituted

640 pyridazinyl. In some embodiments, R² is an unsubsituted pyrimidinyl. In some embodiments,

641 R² is an unsubsituted thienyl. In some embodiments, R² is a chloro-substituted thienyl. In

642 some embodiments, R² is an unsubsituted furyl. In some embodiments, R² is a substituted or

643 unsubsituted morpholinyl. In some embodiments, R² is a substituted or unsubsituted oxanyl.

2 2

644 In some embodiments, R is a substituted or unsubsituted oxetanyl. In some embodiments, R

645 is an unsubsituted morpholinyl. In some embodiments, R² is an unsubsituted oxanyl. In some

646 embodiments, R² is an unsubsituted oxetanyl. In some embodiments, R² is substituted or

647 unsubstituted benzodioxinyl. In some embodiments, R is substituted or unsubstituted

648 naphthyl. In some embodiments, R² is unsubstituted benzodioxinyl. In some embodiments,

649 R² is unsubstituted naphthyl. In some embodiments, R² is substituted or unsubstituted phenyl.

650 In some embodiments, Y is fluorine.

651 [0070] Exemplary compounds, e.g., multisubstituted aromatic compounds, in accordance

652 with the present disclosure are provided herein. In Table A following, compound (Cmpd)

653 number, chemical name (i.e., International Union of Pure and Applied Chemistry [IUPAC]

654 name), molecular weight (MW_cai_c calculated mass) and biological activity (i.e., inhibition

655 activity in a thrombin assay) are disclosed.

656 [0071] For Table A following, the disclosed compounds were assayed for inhibition of the

657 protease activity of thrombin as described herein. In Table A, the level of inhibition in the

658 thrombin assay is indicated as follows: a: ICso < 0.1 μΜ; b: 0.1 μΜ < ICs₀ < 1 μΜ; c: ICs₀ >

659 1 μΜ. Accordingly, in some embodiments, there is provided a compound as expressly set

660 forth in Table A following.

661 Table A.

662

l -(5-[(5-chlorothiophen-2-yl)methyl]amino-4-fluoro-3-(oxan-

416 a 4-yl)-l H-pyrazol- l -yl)-3-hydroxy-2,2-dimethylpropan-l -one

l -(5-[(5-chlorothiophen-2-yl)methyl]amino-4-fluoro-3-(oxan-

430 a 4-yl)- 1 H-pyrazol- 1 -yl)-3-methoxy-2,2-dimethy lpropan- 1 -one

l -(5-[(5-chlorothiophen-2-yl)methyl]amino-4-fluoro-3-

399 a (piperidin-4-y 1)- 1 H-pyrazol- 1 -y l)-2,2-dimethylpropan- 1 -one

l -(5-[(5-chlorothiophen-2-yl)methyl]amino-4-fluoro-3- (piperidin-4-y 1)- 1 H-pyrazol- 1 -y l)-2-methoxy-2-methy lpropan- 415 a 1 -one

l -(5-[(5-chlorothiophen-2-yl)methyl]amino-4-fluoro-3- (piperidin-4-yl)- 1 H-pyrazol- 1 -yl)-3-hydroxy-2,2- 415 a dimethylpropan- 1 -one

l -(5-[(5-chlorothiophen-2-yl)methyl]amino-4-fluoro-3- (piperidin-4-yl)-l H-pyrazol- l -yl)-3-methoxy-2,2- 429 a dimethylpropan- 1 -one

l -(5-[(5-chlorothiophen-2-yl)methyl]amino-4-fluoro-3-phenyl-

392 a 1 H-pyrazol- 1 -yl)-2,2-dimethylpropan- 1 -one

l -(5-[(5-chlorothiophen-2-yl)methyl]amino-4-fluoro-3-phenyl-

394 a 1 H-pyrazol- 1 -yl)-2-hydroxy-2-methylpropan- 1 -one

l -(5-[(5-chlorothiophen-2-yl)methyl]amino-4-fluoro-3-phenyl-

408 a 1 H-pyrazol- 1 -yl)-2-methoxy-2-methylpropan- 1 -one

l -(5-[(5-chlorothiophen-2-yl)methyl]amino-4-fluoro-3-phenyl- 1 H-pyrazol- 1 -yl)-3-(2-methoxyethoxy)-2,2-dimethy lpropan- 1 - 466 a one

l -(5-[(5-chlorothiophen-2-yl)methyl]amino-4-fluoro-3-phenyl-

408 a 1 H-pyrazol- l -yl)-3-hydroxy-2,2-dimethy lpropan- 1 -one

l -(5-[(5-chlorothiophen-2-yl)methyl]amino-4-fluoro-3-phenyl-

422 a 1 H-pyrazol- 1 -yl)-3-methoxy-2,2-dimethylpropan- 1 -one

1 -[4-(5-[(5-chlorothiophen-2-yl)methyl]amino- 1 -(2,2- dimethylpropanoyl)-4-fluoro-lH-pyrazol-3- 475 a yl)phenyl]pyrrolidin-2-one

1 -[4-(5-[(5-chlorothiophen-2-y l)methyl]amino- 1 -(2,3-dihydro- 1 ,4-benzodioxine-5-carbonyl)-4-fluoro-l H-pyrazol-3- 553 a yl)phenyl]pyrrolidin-2-one

l -[4-(5-[(5-chlorothiophen-2-yl)methyl]amino-4-fluoro-l -(2- methoxybenzoy 1)- 1 H-pyrazol-3-yl)phenyl]-2,2,2- 540 c trifluoroethan- 1 -ol

1 -[4-(5-t(5-chlorothiophen-2-yl)methyl]amino-4-fluoro-l-(2-

525 a methoxybenzoyl)- 1 H-pyrazol-3-yl)phenyl]pyrrolidin-2-one

l -[4-(5-[(5-chlorothiophen-2-yl)methyl]amino-4-fluoro-l -

485 c (furan-3-carbonyl)-l H-pyrazol-3-yl)phenyl]pyrrolidin-2-one

1 -[4-(5-[(5-chlorothiophen-2-yl)methy l]amino-4- luoro- 1 H-

399 b pyrazol-3-yl)piperidine- 1 -carbonyl]cyclopropan- 1 -ol l -[5-(benzylamino)-4-fluoro-3-(pyridin-2-yl)-l H-pyrazol-l -yl]-

352 a 2,2-dimethylpropan- 1 -one

1 -[5-(benzylamino)-4-fluoro-3-phenyl- 1 H-pyrazol- 1 -yl]-2,2-

351 a dimethylpropan- 1 -one

l -benzoyl-N-[(5-chlorothiophen-2-yl)methyl]-4-fluoro-3-

420 a (oxan-4-yl)-l H-pyrazol-5-amine

l -benzoyl-N-[(5-chlorothiophen-2-yl)methyl]-4-fluoro-5-

420 c (oxan-4-yl)- 1 H-pyrazol-3-amine

2-(5-[(5-chlorothiophen-2-yl)methyl]amino-4-fluoro-3-phenyl- l H-pyrazole-l -carbonyl)phenyl 5- 661 b (dimethylamino)naphthalene-l -sulfonate

4-(5-[(5-chlorothiophen-2-yl)methyl]amino-4-fluoro-3-phenyl- 1 H-pyrazole- 1 -carbonyl)phenyl 5- 661 c (dimethylamino)naphthalene- 1 -sulfonate

4-[4-(5-[(5-chlorothiophen-2-yl)methyl]amino-l -(2,2- dimethylpropanoyl)-4-fluoro- 1 H-pyrazol-3- 491 a yl)phenyl]mo holin-3-one

6-(5-[(5-chlorothiophen-2-yl)methyl]amino-l -(2,2- dimethylpropanoyl)-4-fluoro- 1 H-pyrazol-3-yl)- 1 ,2,3,4- 460 a tetrahydronaphthalen- 1 -one

6-(5-[(5-chlorothiophen-2-y l)methy l]amino-4-fluoro- 1 -(2- methoxybenzoyl)- 1 H-pyrazol-3-yl)- 1 ,2,3,4- 512 c tetrahydronaphthalen- 1 -ol

6-(5-[(5-chlorothiophen-2-yl)methyl]amino-4-fluoro- 1 -(2- methoxybenzoyl)-l H-pyrazol-3-yl)- 1 ,2,3,4- 510 a tetrahydronaphthalen- 1 -one

N-[(5-chlorothiophen-2-yl)methyl]- l-(2,3-dihydro-l,4- benzodioxine-5-carbonyl)-4-fluoro-3-(oxan-4-yl)-lH-pyrazol- 478 a

5-amine

N-[(5-chlorothiophen-2-yl)methyl]- 1 -(2,3-dihydro- 1 ,4- benzodioxine-5-carbonyl)-4-fluoro-3-(piperidin-4-yl)-l H- 477 a pyrazol-5-amine

N- [(5 -chlorothiophen-2-y l)methy 1]- 1 -(2 , 3 -dihydro- 1,4- benzodioxine-5-carbonyl)-4-fluoro-3-phenyl-l H-pyrazol-5- 470 a amine

N-[(5-chlorothiophen-2-yl)methyl]- l-(2,3-dihydro- l,4- benzodioxine-5-carbony l)-4-fluoro-5-(oxan-4-y 1)- 1 H-pyrazol- 478 c 3 -amine

N-[(5-chlorothiophen-2-yl)methyl]- 1 -(2,4-dimethoxybenzoy 1)-

480 a 4-fluoro-3-(oxan-4-y 1)- 1 H-pyrazol-5-amine

N-[(5-chlorothiophen-2-yl)methyl]-l -(2,4-dimethoxybenzoyl)-

479 a 4-fluoro-3-(piperidin-4-y 1)- 1 H-pyrazol-5-amine

N-[(5-chlorothiophen-2-yl)methyl]- 1 -(2,4-dimethoxybenzoyl)-

472 a 4-fluoro-3 -phenyl- 1 H-pyrazol-5-amine N-[(5-chlorothiophen-2-yl)methyl]-l -(2,4-dimethoxybenzoyl)-

480 c 4-fluoro-5-(oxan-4-yl)-lH-pyrazol-3-amine

N-[(5-chlorothiophen-2-yl)methyl]-3-(l-[5- (dimethylamino)naphthalen-l -yl]sulfony]piperidin-4-yl)-4- 682 c fluoro- 1 -(2-methoxybenzoyl)- 1 H-pyrazol-5-amine

N-[(5-chlorothiophen-2-yl)methyl]-4-fluoro- l -(2-

450 a methoxybenzoy])-3-(oxan-4-yl)-l H-pyrazol-5-amine

N-[(5-chlorothiophen-2-yl)methyl]-4-fluoro-l -(2-

449 a methoxybenzoyl)-3-(piperidin-4-yl)- 1 H-pyrazol-5-amine

N-[(5-chIorothiophen-2-yl)methyl]-4-fluoro-l -(2-

443 a methoxybenzoyl)-3-(pyridin-2-yl)-lH-pyrazol-5-amine

N-[(5-chlorothiophen-2-yl)methyl]-4-fluoro- l-(2-

442 a methoxybenzoyl)-3-phenyl- 1 H-pyrazol-5-amine

N-[(5-chlorothiophen-2-yl)methyl]-4-fluoro-l -(2-

450 c methoxybenzoyl)-5-(oxan-4-yl)- 1 H-pyrazol-3-amine

N-[(5-chlorothiophen-2-yl)methyl]-4-fluoro-l-(3-

406 c methyloxetane-3-carbonyl)-3-phenyl- 1 H-pyrazol-5-amine

N-f(5-chlorothiophen-2-yl)methyl]-4-fluoro-l-(4-methyloxane-

442 a 4-carbonyl)-3-(oxan-4-yl)-lH-pyrazol-5-amine

N-[(5-chlorothiophen-2-yl)methyl]-4-fluoro- 1 -(4-methyloxane-

434 a 4-carbonyl)-3 -phenyl- 1 H-pyrazol-5 -amine

N-[(5-chlorothiophen-2-yl)methyl]-4-fluoro-l-(furan-3-

410 a carbonyl)-3-(oxan-4-yl)- 1 H-pyrazol-5-amine

N-[(5-chlorothiophen-2-yl)methyl]-4-fluoro- l-(furan-3-

409 a carbony l)-3-(piperidin-4-yl)- 1 H-pyrazol-5-amine

N-[(5-chlorothiophen-2-yl)methyl]-4-fluoro- l-(furan-3-

402 a carbonyl)-3-phenyl- lH-pyrazol-5-amine

N-[(5-chlorothiophen-2-yl)methyl]-4-fluoro-l -[4-(2-

494 a methoxyethoxy)benzoyl]-3-(oxan-4-yl)- 1 H-pyrazol-5-amine

Ν-[(5-ο1ι1θΓθΐΗίορ1ΐ6η-2^1)ηΐ6^1]-4-11υοΓθ-1-[4-(ηιθ 1ιο1ίη-4-

505 a yl)benzoyl]-3-(oxan-4-yl)-lH-pyrazol-5-amine

N-[(5-chlorothiophen-2-yl)methyl]-4-fluoro-3-(oxan-4-yl)-l-

426 a (thiophene-3-carbonyl)- 1 H-pyrazol-5-amine

N-[(5-chlorothiophen-2-yl)methyl]-5-(l-[5- (dimethylamino)naphthalen- 1 -yl]sulfony lpiperidin-4-yl)-4- 682 c fluoro- 1 -(2-methoxybenzoyl)- 1 H-pyrazol-3 -amine

N-[(5-chlorothiophen-2-yl)methyl]-N-[4-fluoro-3-(5-oxo- 5,6,7,8-tetrahydronaphthalen-2-yl)- 1 H-pyrazol-5-yl]-2- 510 c methoxybenzamide

N-[4-(5-[(5-chlorothiophen-2-yl)methyl]amino-4-fluoro-3- (piperidin-4-yl)- 1 H-pyrazole- 1 -carbonyl)phenyl]-5- 667 a (dimethy lamino)naphthalene- 1 -sulfonamide N-[4-(5-[(5-chlorothiophen-2-yl)methyl]amino-4-fluoro-3-

58 pheny 1- 1 H-pyrazole- 1 -carbonyl)pheny l]-5- 660 a

(dimethylamino)naphthalene-l -sulfonamide

N-benzyl-4-fluoro- 1 -(2-methoxybenzoyl)-3-(pyridin-2-yl)- 1 H-

59 402 a

pyrazol-5-amine

N-benzyl-4-fluoro- 1 -(2-methoxybenzoyl)-3-phenyl- 1 H-

60 401 a

pyrazol-5-amine

tl -(5-[(5-chlorothiophen-2-yl)methyl]amino-4-fluoro-3-(oxan-

61 414 a

4-y 1)- 1 H-pyrazole- 1 -carbony l)cyclopropy l]methanol

[l-(5-[(5-chlorothiophen-2-yl)methyl]amino-4-fluoro-3-phenyl-

62 406 a

1 H-pyrazole- 1 -carbonyl)cyclopropy ljmethanol

[0072] Compounds disclosed herein also include racemic mixtures, stereoisomers and mixtures of the compounds, including isotopically-labeled and radio-labeled compounds. See e.g., Goding, 1986, MONOCLONAL ANTIBODIES PRINCIPLES AND PRACTICE; Academic Press, p. 104. Such isomers can be isolated by standard resolution techniques, including e.g., fractional crystallization, chiral chromatography, and the like. See e.g., Eliel, E. L. & Wilen S. H., 1993, STEREOCHEMISTRY IN ORGANIC COMPOUNDS ; John Wiley & Sons, New York. [0073] In some embodiments, compounds disclosed herein have asymmetric centers and can occur as racemates, racemic mixtures, and as individual enantiomers or diastereoisomers, with all isomeric forms as well as mixtures thereof being contemplated for use in the compounds and methods described herein. The compounds contemplated for use in the compounds and methods described herein do not include those that are known in the art to be too unstable to synthesize and/or isolate. [0074] The compounds disclosed herein can also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. For example, the compounds can be radiolabeled with radioactive isotopes, such as for example tritium (³H), iodine-125 (¹²⁵1), or carbon-14 (¹⁴C). All isotopic variations of the compounds disclosed herein, whether radioactive or not, are encompassed within the contemplated scope. [0075] In some embodiments, metabolites of the compounds disclosed herein are useful for the methods disclosed herein. [0076] In some embodiments, compounds contemplated herein are provided in the form of a prodrug. The term "prodrug" refers to a compound that can be converted into a compound (e.g., a biologically active compound) described herein in vivo. Prodrugs can be useful for a 687 variety of reason known in the art, including e.g., ease of administration due e.g., to enhanced

688 bioavailable in oral administration, and the like. The prodrug can also have improved

689 solubility in pharmaceutical compositions over the biologically active compounds. An

690 example, without limitation, of a prodrug is a compound which is administered as an ester

691 (i.e., the "prodrug") to facilitate transmittal across a cell membrane where water solubility is

692 detrimental to mobility but which then is metabolically hydrolyzed to the carboxylic acid, the

693 active entity, once inside the cell where water-solubility is beneficial. Conventional

694 procedures for the selection and preparation of suitable prodrug derivatives are described, for

695 example, in DESIGN OF PRODRUGS, (ed. H. Bundgaard, Elsevier, 1985), which is hereby

696 incorporated herein by reference for the limited purpose describing procedures and

697 preparation of suitable prodrug derivatives.

698 [0077] Accordingly, in some embodiments, compounds contemplated herein are provided

699 in the form of a prodrug ester. The term "prodrug ester" refers to derivatives of the

700 compounds disclosed herein formed by the addition of any of a variety of ester-forming

701 groups, e.g., groups known in the art, that are hydrolyzed under physiological conditions.

702 Examples of prodrug ester groups include pivaloyloxymethyl, acetoxy methyl, phthalidyl,

703 indanyl and methoxymethyl, as well as other such groups known in the art, including a (5-R-

704 2-oxo-l ,3-dioxolen-4-yl)methyl group. Other examples of prodrug ester groups can be found

705 in, for example, T. Higuchi and V. Stella, in "Pro-drugs as Novel Delivery Systems", Vol. 14,

706 A.C.S. Symposium Series, American Chemical Society (1975); and BIOREVERSIBLE

707 CARRIERS IN DRUG DESIGN: THEORY AND APPLICATION, edited by E. B. Roche, Pergamon

708 Press: New York, 14-21 (1987) (providing examples of esters useful as prodrugs for

709 compounds containing carboxyl groups). Each of the above-mentioned references is herein

710 incorporated by reference for the limited purpose of disclosing ester- forming groups that can

71 1 form prodrug esters.

712 [0078] In some embodiments, prodrugs can be slowly converted to the compounds described

713 herein useful for the methods described herein when placed in a transdermal patch reservoir

714 with a suitable enzyme or chemical reagent.

715 [0079] Certain compounds disclosed herein can exist in unsolvated forms as well as solvated

716 forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated

717 forms and are encompassed within the scope of contemplated compounds. Certain

718 compounds of the present invention can exist in multiple crystalline or amorphous forms. In 719 general, all physical forms are equivalent for the compounds and methods contemplated

720 herein and are intended to be within the scope disclosed herein.

721 III. Biological Activities

722 [0080] In some embodiments, compounds described herein exhibit inhibitory activity

723 against thrombin with activities > 1 μΜ, e.g., about 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14,

724 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100

725 μΜ, or even greater. In some embodiments, the compounds exhibit inhibitory activity

726 against thrombin with activities between 0.1 μ and 1 μΜ, e.g., about 0.1, 0.2, 0.3, 0.4, 0.5,

727 0.6, 0.7, 0.8, 0.9 or 1.0 μΜ. In some embodiments, compounds described herein exhibit

728 inhibitory activity against thrombin with activities < 0.1 μ , e.g., about 1 , 2, 5, 10, 15, 20,

729 30, 40, 50, 60, 70, 80, 90, or 100 nM. Ranges of values using a combination of any of the

730 values recited herein as upper and/or lower limits are also contemplated, for example, but not

731 limited to, 1 -10 nM, 10-100 nM, 0.1-1 μΜ, 1-10 μΜ, 10-100 μΜ, 100-200 μΜ, 200-500

732 μΜ, or even 500-1000 μΜ. In some embodiments, the inhibitory activity is in the range of

733 about 1 -10 nM, 10-100 nM, 0.1-1 μΜ, 1-10 μΜ, 10-100 μΜ, 100-200 μΜ, 200-500 μΜ, or

734 even 500-1000 μΜ. It is understood that for purposes of quantification, the terms "activity,"

735 "inhibitory activity," "biological activity," "thrombin activity" and the like in the context of

736 an inhibitory compound disclosed herein can be quantified in a variety of ways known in the

737 art. Unless indicated otherwise, as used herein such terms refer to IC50 in the customary

738 sense (i.e., concentration to achieve half-maximal inhibition).

739 [0081] Inhibitory activity against thrombin in turn inhibits the blood coagulation process.

740 Accordingly, compounds disclosed herein are indicated in the treatment or management of

741 thrombotic disorders. In some embodiments, a dose or a therapeutically effective dose of a

742 compound disclosed herein will be that which is sufficient to achieve a plasma concentration

743 of the compound or its active metabolite(s) within a range set forth herein, e.g., about 1 -10

744 nM, 10-100 nM, 0.1-1 μΜ, 1-10 μΜ, 10-100 μΜ, 100-200 μΜ, 200-500 μΜ, or even

745 500-1000 μΜ, preferably about 1 -10 nM, 10-100 nM, or 0.1-1 μΜ. Without wishing to be

746 bound by any theory, it is believe that such compounds are indicated in the treatment or

747 management of thrombotic disorders. 748 IV. Methods of Treating and Preventing Disease

749 [0082] Thrombosis. Thrombotic diseases are the primary indications for thrombin

750 inhibition, because of thrombin's location in the coagulation cascade and, in turn, the

751 importance of the coagulation cascade in the progression of blood clotting processes.

752 However, without wishing to be bound by any theory, it is believed the coagulation cascade

753 in general, and thrombin in particular, is important in a variety other disease states.

754 [0083] It has been discovered that compounds described herein, e.g., multisubstituted

755 aromatic compounds, exhibit inhibitory action against thrombin (activated blood-coagUlation

756 factor II; EC 3.4.21.5). This, in turn inhibits the blood coagulation process.

757 [0084] This inhibitory action is useful in the treatment of a variety of thrombotic disorders,

758 such as, but not limited to, acute vascular diseases such as acute coronary syndromes;

759 venous-, arterial- and cardiogenic thromboembolisms; the prevention of other states such as

760 disseminated intravascular coagulation, or other conditions that involve the presence or the

761 potential formation of a blood clot thrombus. Other indications for methods described herein

762 include the following.

763 [0085] Cancer. It has long been recognized that cancer progression is accompanied by

764 venous thrombosis, but it has not been understood how each disease is related. From several

765 clinical trials studying the treatment of VTE, metaanalyses have shown that low molecular

766 weight heparins (LMWHs) improve overall survival in subgroups of cancer patients. See

767 e.g., Zacharski, L. R. & Lee, A. Y., 2008, Expert Opin Investig Drugs, 17: 1029-1037;

768 Falanga, A. & Piccioli, A., 2005, Current Opinion in Pulmonary Medicine, 1 1 :403-407;

769 Smorenburg, S. M., et al, 1999, Thromb Haemost, 82: 1600-1604; Hettiarachchi, R. J., et al,

770 1999, Thromb Haemost, 82:947-952. This finding was substantiated in later clinical trials

771 that measured specifically the survival of cancer patients. See e.g., Lee, A. Y.et al, 2005, J 111 Clin Oncol, 23:2123-2129; Klerk, C. Y.et al., JClin Oncol 2005, 23 :2130-2135; Kakkar, A.

773 K., et al., 2004, J Clin Oncol, 22: 1944-1948; Altinbas, M., et al., 2004, J Thromb Haemost,

774 2: 1266-1271.

775 [0086] More recently, researchers have focused on the specific anticancer effect of DTIs.

776 For example, it was shown that heparin significantly prolonged the survival of patients with

777 limited small cell lung cancer. See e.g., Akl, E. A., et al., 2008, J Exp Clin Cancer Res, 27:4.

778 Other investigators found that systemic use of argatroban reduced tumor mass and prolonged

779 survival time in rat glioma models leading to the conclusion that argatroban should be

780 considered as a novel therapeutic for glioma, a notoriously difficult to treat cancer type. See 781 e.g., Hua, Y., et al, 2005, Acta Neurochir, Suppl 2005, 95:403-406; Hua, Y., et al, 2005, J

782 Thromb Haemost, 3: 1917-1923. Very recently, it was demonstrated that dabigatran etexilate,

783 a DTI recently FDA-approved (see e.g., Hughes, B., 2010, Nat Rev Drug Discov, 9:903-906)

784 for DVT indications, inhibited both the invasion and metastasis of malignant breast tumors.

785 See e.g., DeFeo, K.et al, 2010, Thrombosis Research, 125 (Supplement 2): S188-S 188;

786 Defeo, K., et al, 2010, Cancer Biol Ther, 10: 1001 -1008. Thus, dabigatran etexilate

787 treatment led to a 50% reduction in tumor volume at 4 weeks with no weight loss in treated

788 mice. Dabigatran etexilate also reduced tumor cells in the blood and liver micrometastases

789 by 50-60%. These investigators concluded that dabigatran etexilate can be beneficial in not

790 only preventing thrombotic events in cancer patients, but also as adjunct therapy to treat

791 malignant tumors.

792 [0087] Further, hirudin and the LMWH nadroparin dramatically reduced the number of

793 lung metastases when administered prior to cancer cell inoculation. See e.g., Hu, L., et al,

794 2004, Blood, 104:2746-51.

795 [0088] The de novo thrombin inhibitor d-Arg-Oic-Pro-d-Ala-Phe(p-Me) has been found to

796 block thrombin-stimulated invasion of prostate cancer cell line PC-3 in a concentration

797 dependent manner. See e.g., Nieman, M. T., et al, 2008, J Thromb Haemost, 6:837-845. A

798 reduced rate of tumor growth was observed in mice dosed with the pentapeptide through their

799 drinking water. The mice also showed reduced fold rate in tumor size and reduced overall

800 tumor weight compared to untreated mice. Microscopic examination of treated tumors

801 showed reduced number of large blood vessels thus concluding that the pentapeptide

802 interfered with tumor angiogenesis. Nieman, M. T., et al, Thromb Haemost, 104: 1044-8.

803 [0089] In view of these and related studies, it is suggested that anticoagulants affect tumor

804 metastasis; that is, angiogenesis, cancer cell adhesion, migration and invasion processes. See

805 e.g., Van Noorden, C. J., et al, 2010, Thromb Res, 125 Suppl 2:S77-79.

806 [0090] Fibrosis. Several studies have shown the utility of anticoagulant therapy in fibrotic

807 disorders. For example, in a rat model of CCl₄-induced chronic liver injury, the DTI

808 SSR182289 decreased liver fibrogenesis significantly after 7 weeks of administration.

809 Similar observations were made in other studies using the LMWHs nadroparin, tinzaparin,

810 enoxaparin, and dalteparin sodium. See e.g., Duplantier, J. G., et al, 2004, Gut, 53: 1682-

81 1 1687; Abdel-Salam, O. M., et al, 2005, Pharmacol Res, 51 :59-67; Assy, N., et al, 2007, Dig

812 Dis Sci, 52: 1 187-1 193; Abe, W., et al, 2007 , J Hepatol, 46:286-294. 813 [0091] In another example, the DTI melagatran greatly reduced ischemia reperfusion injury

814 in a kidney transplant model in the large white pig. This led to a drastically improved kidney

815 graft survival at 3 months. See e.g., Favreau, F., et ai, 2010, Am J Transplant, 10:30-39.

816 [0092] Recent studies have shown that in a bleomycin-induced mouse model of pulmonary

817 fibrosis, dabigatran etexilate treatment reduced important profibrotic events in lung

81 8 fibroblasts, including the production of collagen and connective tissue growth factor. See e.g.,

819 Silver, R. M., et ai, 2010, Am. J. Respir. Crit. Care Med., 181 :A6780; Bogatkevich, G. S., et

820 al. , 2009, Arthritis Rheum, 60:3455-3464.

821 [0093] The above experimental evidence points to a close relationship between thrombin

822 and fibrosis and suggests novel therapeutic opportunities for fibrosis using thrombin

823 inhibitors. See e.g., Calvaruso, V., et al, 2008, Gut, 57: 1722-1727; Chambers, R. C, 2008,

824 Br J Pharmacol, 153 Suppl 1 :S367-378; Chambers, R. C. & Laurent, G. J., 2002, Biochem

825 Soc Trans, 30:194-200; Howell, D. C, et al, 2001 , Am J Pathol, 159: 1383-1395.

826 [0094] Alzheimer's Disease. Very recent experiments confirm higher thrombin levels in

827 brain endothelial cells of patients with Alzheimer's disease. While 'normal' thrombin levels

828 are connected to regulatory CNS functions, thrombin accumulation in the brain is toxic. It

829 has also been found that the neural thrombin inhibitor Protease Nexin 1 (PN-1) is

830 significantly reduced in the Alzheimer's disease brain, despite the fact that PN-1 mRNA

831 levels are unchanged. These observations have led some investigators to suggest that

832 reduction of CNS-resident thrombin will prove useful in Alzheimer's Disease (AD) treatment.

833 See e.g., Vaughan, P. J., et al, 1994, Brain Res, 668: 160-170; Yin, X., et al, 2010, Am J

834 Pathol, 176: 1600-1606; Akiyama, K, et al., 1992, Neurosci Lett, 146: 152-154.

835 [0095] Multiple Sclerosis. Investigators found that hirudin treatment in an animal model

836 of Multiple Sclerosis (MS) showed a dramatic improvement in disease severity. See e.g.,

837 Han, M. H., et ai, 2008, Nature, 451 :1076-1081. Similar results were obtained following

838 treatment with heparin (a DTI) and dermatan sulfate another coagulation inhibitor. See e.g.,

839 Chelmicka-Szorc, E. & Arnason, B. G., 1972, Arch Neurol, 27: 153-158; Inaba, Y., et al,

840 1999, Cell Immunol, 198:96- 102. Other evidence shows that naturally occurring

841 antithrombin III has anti-inflammatory effects in diseases such as endotoxemia and other

842 sepsis-related conditions. See e.g., Wiedermann, C. J. & Romisch, J., 2002, Acta Med

843 Austriaca, 29:89-92. Naturally occurring thrombin inhibitors are presumably synthesized in

844 situ and have protective roles in CNS inflammation. Therefore, therapeutic thrombin

845 inhibition has been proposed as a potential MS treatment. See e.g., Luo, W., et al, 2009, In: 846 THROMBIN, Maragoudakis, M. E.; Tsopanoglou, N. E., Eds. Springer New York: 2009; pp

847 133-159.

848 [0096] Pain. In a rat pain model with partial lesion of the sciatic nerve, intrathecal hirudin

849 prevented the development of neuropathic pain and curbed pain responses for 7 days. The

850 investigators found that following injury, neuropathic pain was mediated by thrombin

851 generation, which in turn activated PAR-1 receptor in the spinal cord. Hirudin inhibited

852 thrombin generation and ultimately led to pain relief. See e.g., Garcia, P. S., et al, 2010,

853 Thromb Haemost, 103: 1 145- 1 151 ; Narita, M., et al., 2005, JNeurosci, 25: 10000-10009.

854 Researchers hypothesize that thrombin and the PARs are involved not just as part of the

855 coagulation cascade, but in inflammation, nociception and neurodevelopment. Development

856 of a DTI to intersect an unexploited pharmacology will lead to pain therapeutics distinct from

857 opioids and NSAIDs, whose shortcomings are well documented. See e.g., Garcia 2010, Id.

858 [0097] Accordingly, in a further aspect, there is provided a method for treating a disease or

859 disorder in a subject in need thereof. The method includes administering a compound of any

860 of Formulae (la), (lb), (Ila) or (lib) as disclosed herein, a compound as set forth in Table A,

861 pharmaceutically acceptable salt, ester, solvate, or prodrug thereof, or pharmaceutical

862 composition thereof, to a subject in need thereof in an amount effective to treat the disease or

863 disorder. The terms "therapeutically effective amount," "amount effective to treat," "amount

864 effective to prevent" and the like refer to that amount of drug or pharmaceutical agent (e.g.,

865 compound or pharmaceutical composition disclosed herein) that will elicit the biological or

866 medical response of a tissue, system, animal, or human that is being sought by a researcher,

867 veterinarian, medical doctor or other clinician.

868 [0098] In some embodiments, the disease or disorder is a thrombotic disease or disorder.

869 In some embodiments, the thrombotic disease or disorder is acute coronary syndrome, venous

870 thromboembolism, arterial thromboembolism or cardiogenic thromboembolism. In some

871 embodiments, the thrombotic disease or disorder is acute coronary syndrome. In some

872 embodiments, the thrombotic disease or disorder is venous thromboembolism. In some

873 embodiments, the thrombotic disease or disorder is arterial thromboembolism. In some

874 embodiments, the thrombotic disease or disorder is cardiogenic thromboembolism.

875 [0099] In some embodiments, the disease or disorder is fibrosis, Alzheimer's Disease,

876 multiple sclerosis, pain, or cancer. In some embodiments, the disease or disorder is

877 Alzheimer's Disease. In some embodiments, the disease or disorder is multiple sclerosis. 878 [0100] In some embodiments, the disease or disorder is fibrosis. In some embodiments

879 contemplating fibrosis, the method is directed to treating chronic liver injury. In some

880 embodiments, the disease or disorder is ischemia reperfusion injury. In some embodiments,

881 the disease or disorder is pulmonary fibrosis.

882 [0101] In some embodiments, the disease or disorder is pain. In some embodiments, the

883 pain is neuropathic pain.

884 [0102] In some embodiments, the disease or disorder is cancer. In some embodiments, the

885 cancer is limited small cell lung cancer. In some embodiments, the cancer is a glioma. In

886 some embodiments, the cancer is malignant breast cancer. In some embodiments, the cancer

887 is a micrometastasis. In some embodiments, the micrometastasis is of the blood or liver. In

888 some embodiments, the cancer is a lung metastasis. In some embodiments, the cancer is

889 prostatic cancer.

890 [0103] In another aspect, there is provided a method for preventing a disease or disorder in

891 a subject. The method includes administering a compound of any of Formulae (la), (lb), (Ila)

892 or (lib) as disclosed herein, compound as set forth in Table A herein, pharmaceutically

893 acceptable salt, ester, solvate, or prodrug thereof, or pharmaceutical composition thereof, to a

894 subject in need thereof in an amount effective to prevent the disease or disorder.

895 [0104] In some embodiments, the disease or disorder is a thrombotic disorder. In some

896 embodiments, the thrombotic disorder is acute coronary syndrome, venous

897 thromboembolism, arterial thromboembolism or cardiogenic thromboembolism. In some

898 embodiments, the thrombotic disease or disorder is disseminated intravascular coagulation.

899 In some embodiments, the thrombotic disorder involves the presence or the potential

900 formation of a blood clot thrombus.

901 [0105] Yet further to this aspect, in some embodiments, the disease or disorder is fibrosis,

902 Alzheimer's Disease, multiple sclerosis, pain, or cancer. In some embodiments, the disease

903 or disorder is fibrosis. In some embodiments, the disease or disorder is Alzheimer's Disease.

904 In some embodiments, the disease or disorder is multiple sclerosis. In some embodiments,

905 the disease or disorder is pain. In some embodiments, the disease or disorder is cancer.

906 V. Assays

907 [0106] Compounds described herein can be assayed, by a variety of methods known in the

908 art and described herein, for inhibition of biological activity, e.g., protease activity, of a

909 variety of proteins, e.g., thrombin. For example, the protease activity of such proteins, e.g., 910 thrombin, can be monitored using a chromophoric substrate, e.g., a p-nitroanilide peptide

91 1 substrate, which upon hydrolysis releases p-nitroanilide, which in turn gives rise to a color

912 change which can be determined spectrophotometrically. See e.g., Lottenberg, R, et al,

913 1983, Biochemica et Biophysica Acta, 752:539-557. Accordingly, the change in color can be

914 monitored with a spectrophotometer at e.g., 405 nm to provide a signal which is directly

915 proportional to the proteolytic activity of the enzyme.

916 [0107] The thrombin activity reported herein (e.g., Table A) was obtained as follows.

917 Human thrombin was obtained from Haematologic Technologies Inc. The chromogenic

918 substrate S-2238 was obtained from DiaPharma. Thrombin was assayed in buffer containing

919 0.05 M Tris (pH 7.4), 0.015 M NaCl and 0.01 % PEG-8000. The final concentration of

920 enzyme used was 3 nM thrombin. The final concentration of substrate used was 125 μΜ S-

921 2238 for thrombin. All assays were performed in 96-well microtiter plates at room

922 temperature (RT). The enzyme and inhibitor were pre-incubated for 10 minutes then

923 substrate was added and read at 405 nm in a SpectraMax Plus Spectrophotometer (Molecular

924 Devices). Inhibitor IC50 values were determined by adding test compound as ten point, three-

925 fold serial dilutions in buffer solution, as known in the art. The plate was read at 10 minutes

926 after substrate addition. The IC50 was calculated by plotting the percent (%) inhibition

927 against compound concentration and fitting the data to a constrained four parameter

928 sigmoidal curve, as known in the art.

929 VI. Pharmaceutical Compositions

930 [0108] In another aspect, there is provided a pharmaceutical composition comprising a

931 compound disclosed herein and a pharmaceutically acceptable excipient. The compound is a

932 compound of any of Formulae (la), (lb), (Ila) or (lib) as disclosed herein, a compound as set

933 forth in Table A herein, or pharmaceutically acceptable salt, ester, solvate, or prodrug thereof.

934 In some embodiments, the compound is set forth in Table A herein.

935 [0109] The term "pharmaceutically acceptable salts" is meant to include salts of the active

936 compounds that are prepared with relatively nontoxic acids or bases, depending on the

937 particular substituents found on the compounds described herein. When compounds

938 disclosed herein contain relatively acidic functionalities, base addition salts can be obtained

939 by contacting the neutral form of such compounds with a sufficient amount of the desired

940 base, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable base

941 addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium

942 salt, or a similar salt. When compounds disclosed herein contain relatively basic 943 functionalities, acid addition salts can be obtained by contacting the neutral form of such

944 compounds with a sufficient amount of the desired acid, either neat or in a suitable inert

945 solvent. Examples of pharmaceutically acceptable acid addition salts include those derived

946 from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic,

947 monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric,

948 sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the

949 salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, maleic,

950 malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic, phthalic, benzenesulfonic, p-

951 tolylsulfonic, citric, tartaric, oxalic, methanesulfonic, and the like. Also included are salts of

952 amino acids such as arginate and the like, and salts of organic acids like glucuronic or

953 galactunoric acids and the like (see, for example, Berge et al, "Pharmaceutical Salts",

954 Journal of Pharmaceutical Science, 1977, 66, 1-19). Certain specific compounds disclosed

955 herein contain both basic and acidic functionalities that allow the compounds to be converted

956 into either base or acid addition salts.

957 [0110] Compounds disclosed herein can exist as salts, such as with pharmaceutically

958 acceptable acids. Accordingly, the compounds contemplated herein include such salts.

959 Examples of such salts include hydrochlorides, hydrobromides, sulfates, methanesulfonates,

960 nitrates, maleates, acetates, citrates, fumarates, tartrates (e.g., (+)-tartrates, (-)-tartrates, or

961 mixtures thereof including racemic mixtures), succinates, benzoates, and salts with amino

962 acids such as glutamic acid. These salts can be prepared by methods known to those skilled

963 in the art.

964 [0111] The neutral forms of the compounds are preferably regenerated by contacting the

965 salt with a base or acid and isolating the parent compound in the conventional manner. The

966 parent form of the compound differs from the various salt forms in certain physical

967 properties, such as solubility in polar solvents.

968 [0112] Pharmaceutically acceptable salts of the compounds above, where a basic or acidic

969 group is present in the structure, are also included within the scope of compounds

970 contemplated herein. When an acidic substituent is present, such as -NHSO3H, -COOH and

971 -P(0)(OH)2, there can be formed the ammonium, sodium, potassium, calcium salt, and the

972 like, for use as the dosage form. Basic groups, such as amino or basic heteroaryl radicals, or

973 pyridyl and acidic salts, such as hydrochloride, hydrobromide, acetate, maleate, palmoate,

974 methanesulfonate, p-toluenesulfonate, and the like, can be used as the dosage form. 975 [0113] Also, in the embodiments in which R-COOH is present, pharmaceutically

976 acceptable esters can be employed, e. g. , methyl, ethyl, tert-butyl, pivaloyloxymethyl, and

977 the like, and those esters known in the art for modifying solubility or hydrolysis

978 characteristics for use as sustained release or prodrug formulations.

979 A. Formulations

980 [0114] The compounds disclosed herein can be prepared and administered in a wide variety

981 of oral, parenteral, and topical dosage forms. Thus, the compounds can be administered by

982 injection (e.g. intravenously, intramuscularly, intracutaneously, subcutaneously,

983 intraduodenally, or intraperitoneally). Also, the compounds described herein can be

984 administered by inhalation, for example, intranasally. Additionally, the compounds disclosed

985 herein can be administered transdermally. It is also envisioned that multiple routes of

986 administration (e.g., intramuscular, oral, transdermal) can be used to administer the

987 compounds disclosed herein. In some embodiments, the compounds disclosed herein can be

988 administered orally as tablets, aqueous or oily suspensions, lozenges, troches, powders,

989 granules, emulsions, capsules, syrups or elixirs. The composition for oral use can contain one

990 or more agents selected from the group of sweetening agents, flavoring agents, coloring

991 agents and preserving agents in order to produce pharmaceutically elegant and palatable

992 preparations. Accordingly, there are also provided pharmaceutical compositions comprising

993 a pharmaceutically acceptable carrier or excipient and one or more compounds disclosed

994 herein.

995 [0115] In some embodiments, tablets contain the acting ingredient in admixture with non- 996 toxic pharmaceutically acceptable excipients that are suitable for the manufacture of tablets.

997 These excipients can be, for example, (1) inert diluents, such as calcium carbonate, lactose,

998 calcium phosphate, carboxymethylcellulose, or sodium phosphate; (2) granulating and

999 disintegrating agents, such as corn starch or alginic acid; (3) binding agents, such as starch,

1000 gelatin or acacia; and (4) lubricating agents, such as magnesium stearate, stearic acid or talc.

1001 These tablets can be uncoated or coated by known techniques to delay disintegration and

1002 absorption in the gastrointestinal tract and thereby provide a sustained action over a longer

1003 period. For example, a time delay material such as glyceryl monostearate or glyceryl

1004 distearate can be employed.

1005 [0116] For preparing pharmaceutical compositions from the compounds disclosed herein,

1006 pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations

1007 include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A 1008 solid carrier can be one or more substance that can also act as diluents, flavoring agents,

1009 binders, preservatives, tablet disintegrating agents, or an encapsulating material.

1010 [0117] A compound disclosed herein, in the form of a free compound or a

101 1 pharmaceutically-acceptable pro-drug, metabolite, analogue, derivative, solvate or salt, can

1012 be administered, for in vivo application, parenterally by injection or by gradual perfusion

1013 over time. Administration can be intravenously, intraperitoneally, intramuscularly,

1014 subcutaneously, intracavity, or transdermally . For in vitro studies the compounds can be

1015 added or dissolved in an appropriate biologically acceptable buffer and added to a cell or

1016 tissue.

1017 [0118] In powders, the carrier is a finely divided solid in a mixture with the finely divided

1018 active component. In tablets, the active component is mixed with the carrier having the

1019 necessary binding properties in suitable proportions and compacted in the shape and size

1020 desired.

1021 [0119] The powders and tablets preferably contain from 5% to 70% of the active compound.

1022 Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin,

1023 dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low

1024 melting wax, cocoa butter, and the like. The term "preparation" is intended to include the

1025 formulation of the active compound with encapsulating material as a carrier providing a

1026 capsule in which the active component with or without other carriers, is surrounded by a

1027 carrier, which is thus in association with it. Similarly, cachets and lozenges are included.

1028 Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms

1029 suitable for oral administration.

1030 [0120] For preparing suppositories, a low melting wax, such as a mixture of fatty acid

1031 glycerides or cocoa butter, is first melted and the active component is dispersed

1032 homogeneously therein, as by stirring. The molten homogeneous mixture is then poured into

1033 convenient sized molds, allowed to cool, and thereby to solidify.

1034 [0121] Liquid form preparations include solutions, suspensions, and emulsions, for example,

1035 water or water/propylene glycol solutions. For parenteral injection, liquid preparations can

1036 be formulated in solution in aqueous polyethylene glycol solution.

1037 [0122] When parenteral application is needed or desired, particularly suitable admixtures for

1038 the compounds disclosed herein are injectable, sterile solutions, preferably oily or aqueous

1039 solutions, as well as suspensions, emulsions, or implants, including suppositories. In 1040 particular, carriers for parenteral administration include aqueous solutions of dextrose, saline,

1041 pure water, ethanol, glycerol, propylene glycol, peanut oil, sesame oil, polyoxyethylene-block

1042 polymers, and the like. Ampoules are convenient unit dosages. The compounds disclosed

1043 herein can also be incorporated into liposomes or administered via transdermal pumps or

1044 patches. Pharmaceutical admixtures suitable for use in the pharmaceuticals compositions and

1045 methods disclosed herein include those described, for example, in PHARMACEUTICAL

1046 SCIENCES (17th Ed., Mack Pub. Co., Easton, PA) and WO 96/05309, the teachings of both of

1047 which are hereby incorporated by reference.

1048 [0123] In some embodiments, preparations for parenteral administration include sterile

1049 aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous

1050 solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and

1051 injectable organic esters such as ethyl oleate. Aqueous carriers include water,

1052 alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media.

1053 Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium

1054 chloride, lactated Ringer's intravenous vehicles include fluid and nutrient replenishers,

1055 electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives

1056 and other additives can also be present such as, for example, antimicrobials, anti-oxidants,

1057 chelating agents, growth factors and inert gases and the like.

1058 [0124] Aqueous solutions suitable for oral use can be prepared by dissolving the active

1059 component in water and adding suitable colorants, flavors, stabilizers, and thickening agents

1060 as desired. Aqueous suspensions suitable for oral use can be made by dispersing the finely

1061 divided active component in water with viscous material, such as natural or synthetic gums,

1062 resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending

1063 agents.

1064 [0125] Also included are solid form preparations that are intended to be converted, shortly

1065 before use, to liquid form preparations for oral administration. Such liquid forms include

1066 solutions, suspensions, and emulsions. These preparations can contain, in addition to the

1067 active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners,

1068 dispersants, thickeners, solubilizing agents, and the like.

1069 [0126] The pharmaceutical preparation is preferably in unit dosage form. In such form the

1070 preparation is subdivided into unit doses containing appropriate quantities of the active

1071 component. The unit dosage form can be a packaged preparation, the package containing

1072 discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or 1073 ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it

1074 can be the appropriate number of any of these in packaged form.

1075 [0127] The quantity of active component in a unit dose preparation can be varied or adjusted

1076 from 0.1 mg to 10000 mg, more typically 1 .0 mg to 1000 mg, most typically 10 mg to 500

1077 mg, according to the particular application and the potency of the active component. The

1078 composition can, if desired, also contain other compatible therapeutic agents.

1079 [0128] Some compounds can have limited solubility in water and therefore can require a

1080 surfactant or other appropriate co-solvent in the composition. Such co-solvents include:

1081 Polysorbate 20, 60, and 80; Pluronic F-68, F-84, and P-103; cyclodextrin; and polyoxyl 35

1082 castor oil. Such co-solvents are typically employed at a level between about 0.01 % and

1083 about 2% by weight.

1084 [0129] Viscosity greater than that of simple aqueous solutions can be desirable to decrease

1085 variability in dispensing the formulations, to decrease physical separation of components of a

1086 suspension or emulsion of formulation, and/or otherwise to improve the formulation. Such

1087 viscosity building agents include, for example, polyvinyl alcohol, polyvinyl pyrrolidone,

1088 methyl cellulose, hydroxy propyl methylcellulose, hydroxyethyl cellulose, carboxymethyl

1089 cellulose, hydroxy propyl cellulose, chondroitin sulfate and salts thereof, hyaluronic acid and

1090 salts thereof, and combinations of the foregoing. Such agents are typically employed at a

1091 level between about 0.01 % and about 2% by weight.

1092 [0130] The compositions disclosed herein can additionally include components to provide

1093 sustained release and/or comfort. Such components include high molecular weight, anionic

1094 mucomimetic polymers, gelling polysaccharides, and finely-divided drug carrier substrates.

1095 These components are discussed in greater detail in U.S. Pat. Nos. 4,91 1 ,920; 5,403,841 ;

1096 5,212, 162; and 4,861 ,760. The entire contents of these patents are incorporated herein by

1097 reference in their entirety for all purposes.

1098 [0131] By the present, there are provided methods for ameliorating wound healing and for

1099 mediating tissue repair (including but not limited to treatment of peripheral and coronary

1 100 vascular disease). According to these methods, a subject having a wound or in need of tissue

1 101 repair, is treated at the site of the wound or damaged tissue or treated systemically, with a

1 102 compound disclosed herein in the form of a free compound or a pharmaceutically-acceptable

1 103 prodrug, metabolite, analogue, derivative, solvate or salt. 1 104 [0132] Generally, the terms "treating", "treatment" and the like are used herein to mean

1 105 affecting a subject, tissue or cell to obtain a desired pharmacologic and/or physiologic effect.

1 106 The effect can be prophylactic in terms of completely or partially preventing a disease or

1 107 disorder or sign or symptom thereof, and/or can be therapeutic in terms of a partial or

1 108 complete cure for a disorder and/or adverse effect attributable to it. "Treating" as used herein

1 109 covers any treatment of, or prevention of a disease or disorder in a vertebrate, a mammal,

1 1 10 particularly a human, and includes: (a) preventing the disease or disorder from occurring in a

1 1 1 1 subject that can be predisposed to the disease or disorder, but has not yet been diagnosed as

1 1 12 having it; (b) inhibiting the disease or disorder, i. e. , arresting its development; or (c)

1 1 13 relieving or ameliorating the disease or disorder, i. e. , cause regression of the disease or

1 1 14 disorder.

1 1 1 [0133] There are provided various pharmaceutical compositions useful for ameliorating

1 1 16 diseases and disorders, including thrombosis. In some embodiments, the disease or disorder

1 1 17 is a thrombotic disorder. In some embodiments, the disease or disorder is acute coronary

1 1 18 syndrome, venous thromboembolism, arterial thromboembolism or cardiogenic

1 1 19 thromboembolism. In some embodiments, the disease or disorder is fibrosis. In some

1 120 embodiments, the disease or disorder is Alzheimer's Disease. In some embodiments, the

1 121 disease or disorder is multiple sclerosis. In some embodiments, the disease or disorder is

1 122 pain. In some embodiments, the disease or disorder is cancer. The pharmaceutical

1 123 compositions according to one embodiment are prepared by formulating a compound

1 124 disclosed herein in the form of a free compound or a pharmaceutically-acceptable pro-drug,

1 125 metabolite, analogue, derivative, solvate or salt, either alone or together with other

1 126 pharmaceutical agents, suitable for administration to a subject using carriers, excipients and

1 127 additives or auxiliaries. Frequently used carriers or auxiliaries include magnesium carbonate,

1 128 titanium dioxide, lactose, mannitol and other sugars, talc, milk protein, gelatin, starch,

1 129 vitamins, cellulose and its derivatives, animal and vegetable oils, polyethylene glycols and

1 130 solvents, such as sterile water, alcohols, glycerol and polyhydric alcohols. Intravenous

1 131 vehicles include fluid and nutrient replenishers.

1 132 [0134] Preservatives include antimicrobial, anti-oxidants, chelating agents and inert gases.

1 133 Other pharmaceutically acceptable carriers include aqueous solutions, non-toxic excipients,

1 134 including salts, preservatives, buffers and the like, as described, for instance, in Remington's

1 135 Pharmaceutical Sciences, 15th ed. Easton: Mack Publishing Co. , 1405-1412, 1461-1487

1 136 (1975) and The National Formulary XIV., 14th ed. Washington: American Pharmaceutical

1 137 Association (1975), the contents of which are hereby incorporated by reference. The pH and 1 138 exact concentration of the various components of the pharmaceutical composition are

1 139 adjusted according to routine skills in the art. See e.g., Goodman and Gilman (eds.), 1990,

1 140 THE PHARMACOLOGICAL BASIS FOR THERAPEUTICS (7th ed.).

1 141 [0135] The pharmaceutical compositions are preferably prepared and administered in dose

1 142 units. Solid dose units are tablets, capsules and suppositories. For treatment of a subject,

1 143 depending on activity of the compound, manner of administration, nature and severity of the

1 144 disease or disorder, age and body weight of the subject, different daily doses can be used.

1 145 [0136] Under certain circumstances, however, higher or lower daily doses can be

1 146 appropriate. The administration of the daily dose can be carried out both by single

1 147 administration in the form of an individual dose unit or else several smaller dose units and

1 148 also by multiple administrations of subdivided doses at specific intervals.

1 149 [0137] The pharmaceutical compositions contemplated herein can be administered locally

1 150 or systemically in a therapeutically effective dose. Amounts effective for this use will, of

1 151 course, depend on the severity of the disease or disorder and the weight and general state of

1152 the subject. Typically, dosages used in vitro can provide useful guidance in the amounts

1 153 useful for in situ administration of the pharmaceutical composition, and animal models can be

1 154 used to determine effective dosages for treatment of particular disorders.

1 155 [0138] Various considerations are described, e. g. , in Langer, 1990, Science, 249: 1527;

1 156 Goodman and Gilman's (eds.), 1990, Id., each of which is herein incorporated by reference

1 157 and for all purposes. Dosages for parenteral administration of active pharmaceutical agents

1 158 can be converted into corresponding dosages for oral administration by multiplying

1 159 parenteral dosages by appropriate conversion factors. As to general applications, the

1 160 parenteral dosage in mg/m2 times 1.8 = the corresponding oral dosage in milligrams ("mg").

1 161 As to oncology applications, the parenteral dosage in mg/m2 times 1.6 = the corresponding

1 162 oral dosage in mg. An average adult weighs about 70 kg. See e.g., Miller-Keane, 1992,

1 163 ENCYCLOPEDIA & DICTIONARY OF MEDICINE, NURSING & ALLIED HEALTH, 5th Ed., (W. B.

1 164 Saunders Co.), pp. 1708 and 1651.

1 165 [0139] The method by which the compound disclosed herein can be administered for oral

1 166 use would be, for example, in a hard gelatin capsule wherein the active ingredient is mixed

1 167 with an inert solid diluent, or soft gelatin capsule, wherein the active ingredient is mixed with

1 168 a co-solvent mixture, such as PEG 400 containing Tween-20. A compound disclosed herein

1 169 can also be administered in the form of a sterile injectable aqueous or oleaginous solution or 1 170 suspension. The compound can generally be administered intravenously or as an oral dose of

1 171 0.1 ug to 20 mg/kg given, for example, every 3 - 12 hours.

1 172 [0140] Formulations for oral use can be in the form of hard gelatin capsules wherein the

1 173 active ingredient is mixed with an inert solid diluent, for example, calcium carbonate,

1 174 calcium phosphate or kaolin. They can also be in the form of soft gelatin capsules wherein

1 175 the active ingredient is mixed with water or an oil medium, such as peanut oil, liquid paraffin

1 176 or olive oil.

1 177 [0141] Aqueous suspensions normally contain the active materials in admixture with

1 178 excipients suitable for the manufacture of aqueous suspension. Such excipients can be (1 )

1 179 suspending agent such as sodium carboxymethyl cellulose, methyl cellulose,

1 180 hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and

1 181 gum acacia; (2) dispersing or wetting agents which can be (a) naturally occurring phosphatide

1 182 such as lecithin; (b) a condensation product of an alkylene oxide with a fatty acid, for

1 183 example, polyoxyethylene stearate ; (c) a condensation product of ethylene oxide with a long

1 184 chain aliphatic alcohol, for example, heptadecaethylenoxycetanol; (d) a condensation product

1 185 of ethylene oxide with a partial ester derived from a fatty acid and hexitol such as

1 186 polyoxyethylene sorbitol monooleate, or (e) a condensation product of ethylene oxide with a

1 187 partial ester derived from fatty acids and hexitol anhydrides, for example polyoxyethylene

1 188 sorbitan monooleate.

1 189 [0142] The pharmaceutical compositions can be in the form of a sterile injectable aqueous

1 190 or oleagenous suspension. This suspension can be formulated according to known methods

1 191 using those suitable dispersing or wetting agents and suspending agents that have been

1 192 mentioned above. The sterile injectable preparation can also a sterile injectable solution or

1 193 suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a

1 194 solution in 1 ,3-butanediol. Among the acceptable vehicles and solvents that can be employed

1 195 are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed

1 196 oils are conventionally employed as a solvent or suspending medium. For this purpose, any

1 197 bland fixed oil can be employed including synthetic mono-or diglycerides. In addition, fatty

1 198 acids such as oleic acid find use in the preparation of injectables.

1 199 [0143] A compound disclosed herein can also be administered in the form of suppositories

1200 for rectal administration of the drug. These compositions can be prepared by mixing the drug

1201 with a suitable non-irritating excipient that is solid at ordinary temperature but liquid at the 1202 rectal temperature and will therefore melt in the rectum to release the drug. Such materials

1203 include cocoa butter and polyethylene glycols.

1204 [0144] The compounds disclosed herein as used in the methods disclosed herein can also be

1205 administered in the form of liposome delivery systems, such as small unilamellar vesicles,

1206 large unilamellar vesicles, and multilamellar vesicles. Liposomes can be formed from a

1207 variety of phospholipids, such as cholesterol, stearylamine, or phosphatidylcholines.

1208 [0145] For topical use, creams, ointments, jellies, solutions or suspensions, etc. , containing

1209 the compounds disclosed herein, are employed.

1210 [0146] In addition, some of the compounds disclosed herein can form solvates with water

121 1 or common organic solvents. Such solvates are encompassed within the scope of the

1212 methods contemplated herein.

1213 B. Effective Dosages

1214 [0147] Pharmaceutical compositions provided herein include compositions wherein the

1215 active ingredient is contained in a therapeutically effective amount, i.e., in an amount

1216 effective to achieve its intended purpose. The actual amount effective for a particular

1217 application will depend, inter alia, on the condition being treated. For example, when

1218 administered in methods to treat thrombosis, such compositions will contain an amount of

1219 active ingredient effective to achieve the desired result (e.g. decreasing the extent of the

1220 thrombosis).

1221 [0148] The dosage and frequency (single or multiple doses) of compound administered can

1222 vary depending upon a variety of factors, including route of administration; size, age, sex,

1223 health, body weight, body mass index, and diet of the recipient; nature and extent of

1224 symptoms of the disease being treated (e.g., the disease responsive to inhibition of thrombin);

1225 presence of other diseases or other health-related problems; kind of concurrent treatment; and

1226 complications from any disease or treatment regimen. Other therapeutic regimens or agents

1227 can be used in conjunction with the methods and compounds disclosed herein.

1228 [0149] For any compound described herein, the therapeutically effective amount can be

1229 initially determined from a variety of techniques known in the art, e.g., biochemical

1230 characterization of inhibition of thrombin, cell culture assays, and the like. Target

1231 concentrations will be those concentrations of active compound(s) that are capable of

1232 decreasing thrombin enzymatic activity as measured, for example, using the methods

1233 described. 1234 [0150] Therapeutically effective amounts for use in humans can be determined from animal

1235 models. For example, a dose for humans can be formulated to achieve a concentration that

1236 has been found to be effective in animals. The dosage in humans can be adjusted by

1237 monitoring thrombin inhibition and adjusting the dosage upwards or downwards, as described

1238 above.

1239 [0151] Dosages can be varied depending upon the requirements of the patient and the

1240 compound being employed. The dose administered to a patient, in the context of the methods

1241 disclosed herein, should be sufficient to affect a beneficial therapeutic response in the patient

1242 over time. The size of the dose also will be determined by the existence, nature, and extent of

1243 any adverse side effects. Generally, treatment is initiated with smaller dosages, which are

1244 less than the optimum dose of the compound. Thereafter, the dosage is increased by small

1245 increments until the optimum effect under circumstances is reached. In some embodiments

1246 of a method disclosed herein, the dosage range is 0.001% to 10% w/v. In some

1247 embodiments, the dosage range is 0.1 % to 5% w/v.

1248 [0152] Dosage amounts and intervals can be adjusted individually to provide levels of the

1249 administered compound effective for the particular clinical indication being treated. This will

1250 provide a therapeutic regimen that is commensurate with the severity of the individual's

1251 disease state.

1252 [0153] Utilizing the teachings provided herein, an effective prophylactic or therapeutic

1253 treatment regimen can be planned that does not cause substantial toxicity and yet is entirely

1254 effective to treat the clinical symptoms demonstrated by the particular patient. This planning

1255 should involve the careful choice of active compound by considering factors such as

1256 compound potency, relative bioavailability, patient body weight, presence and severity of

1257 adverse side effects, preferred mode of administration, and the toxicity profile of the selected

1258 agent.

1259 [0154] Accordingly, in some embodiments, dosage levels of the compounds disclosed

1260 herein as used in the present methods are of the order of e.g., about 0.1 mg to about 1 mg,

1261 about 1 mg to about 10 mg, about 0.5 mg to about 20 mg per kilogram body weight, an

1262 average adult weighing 70 kilograms, with a preferred dosage range between about 0.1 mg to

1263 about 20 mg per kilogram body weight per day (from about 0.7 mg to about 1.4 gm per

1264 patient per day). The amount of the compound disclosed herein that can be combined with the

1265 carrier materials to produce a single dosage will vary depending upon the host treated and the

1266 particular mode of administration. For example, a formulation intended for oral 1267 administration to humans can contain about 5 ug to 1 g of a compound disclosed herein with

1268 an appropriate and convenient amount of carrier material that can vary from about 5 to 95

1269 percent of the total composition. Dosage unit forms will generally contain between from

1270 about 0.1 mg to 500 mg of a compound disclosed herein.

1271 [0155] It will be understood, however, that the specific dose level for any particular patient

1272 will depend upon a variety of factors including the activity of the specific compound

1273 employed, the age, body weight, general health, sex, diet, time of administration, route of

1274 administration, rate of excretion, drug combination and the severity of the particular disease

1275 undergoing therapy.

1276 C. Toxicity

1277 [0156] The ratio between toxicity and therapeutic effect for a particular compound is its

1278 therapeutic index and can be expressed as the ratio between LD50 (the amount of compound

1279 lethal in 50% of the population) and EDso (the amount of compound effective in 50% of the

1280 population). Compounds that exhibit high therapeutic indices are preferred. Therapeutic

1281 index data obtained from in vitro assays, cell culture assays and/or animal studies can be used

1282 in formulating a range of dosages for use in humans. The dosage of such compounds

1283 preferably lies within a range of plasma concentrations that include the ED50 with little or no

1284 toxicity. The dosage can vary within this range depending upon the dosage form employed

1285 and the route of administration utilized. See, e.g. Fingl et al, In: THE PHARMACOLOGICAL

1286 BASIS OF THERAPEUTICS, Ch.l , p.l, 1975. The exact formulation, route of administration, and

1287 dosage can be chosen by the individual practitioner in view of the patient's condition and the

1288 particular method in which the compound is used. For in vitro formulations, the exact

1289 formulation and dosage can be chosen by the individual practitioner in view of the patient's

1290 condition and the particular method in which the compound is used.

1291 VII. Examples

1292 [0157] The examples below are meant to illustrate certain embodiments of the invention and

1293 not to limit the scope of the invention. Abbreviations used herein have their conventional

1294 meaning in the art, unless indicated otherwise. Specific abbreviations include the following:

1295 A = Angstrom; Ac₂0 = acetic anhydride; AcOH = acetic acid; aq = aqueous; Bt =

1296 benzotriazole; BOC = N-teri-butoxycarbonyl; br = broad; i-BuOH = teri-butanol; °C = degree

1297 Celsius; d = doublet; DABCO = l ,4-diazabicyclo[2.2.2]octane; DCE = 1 ,2-dichloroethane;

1298 DCM = dichloromethane; dd = doublet of doublets; DIEA = diethylisopropylamine; DMAP = 1299 4-dimethylaminopyridine; DMF = NN-dimethylformamide; DMSO = dimethylsulfoxide; δ =

1300 chemical shift (given in ppm, unless otherwise indicated); EDCI = l -ethyl-3-(3-

1301 dimethylaminopropyl)carbodiimide; eq = equivalent; Et₂0 = diethyl ether; Et3 =

1302 triethylamine; EtOAc = ethyl acetate; EtOH = ethanol; g = gram; h (or hr) = hour; HOBt =

1303 hydroxybenzotriazole; HPLC = high performance liquid chromatography; Hz = Hertz; IC50 =

1304 inhibitory concentration at 50% inhibition; J = coupling constant (given in Hz, unless

1305 otherwise indicated); LC = liquid chromatography; LHMDS = lithium hexamethyldisilazide;

1306 m = multiplet; M = molar; [M+H]⁺ = parent mass spectrum peak plus FT^"; MS = mass

1307 spectrum; ms = molecular sieves; MP = melting point; Me₂NH = dimethylamine; MeOH =

1308 methanol; mg = milligram; mL = milliliter; mM = millimolar; mmol = millimole; min =

1309 minute; μΐ,. = microliter; μΜ = micromolar; ng = nanogram; nM = nanomolar; NMR =

1310 nuclear magnetic resonance; ppm = parts per million; q = quartet; R_f = retention factor; RT

131 1 = room temperature; s = singlet; t = triplet; TFA = trifluoroacetic acid; THF =

1312 tetrahydrofuran; TLC = thin layer chromatography.

1313

1314 Example 1 - Preparation of Intermediate 1

1315 [0158] General Scheme I. A synthetic scheme useful for synthesis of compounds

1316 described herein is disclosed in General Scheme I following, wherein the terms "R""^'^" _s

1317 and "R^z" are independently hydrogen, substituted or unsubstituted alkyl, substituted or

1318 unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted

1319 heterocycloalkyl, substituted or unsubstituted heterocycloalkenyl, substituted or unsubstituted

1320 aryl, or substituted or unsubstituted heteroaryl, or other groups obvious to those skilled in the

1321 art.

1323 [0159] The synthesis of Intermediate 1 followed General Procedure 1 following.

1324 General Procedure 1

1326 Intermediate 1

1327 To a cold (-78 °C) solution of benzoyl chloride (5.0 mmol, 1.0 eq) and fluoroacetonitrile

1328 (278 μί, 5.0 mmol, 1.0 eq) in dry THF (15 mL) was added a solution of LHMDS in THF (1

1329 M, 10 mL, 10.0 mmol, 2.0 eq). The mixture was allowed to reach room temperature, and IN

1330 HC1 was added dropwise achieving pH 2. The mixture was concentrated under reduced

1331 pressure to afford intermediate 1 in a form pure enough for the next step.

1332 Example 2 - Preparation of Intermediate 2

1335 [0160] General Procedure 1 was followed to obtain Intermediate 2. Thus, to a cold (-78

1336 °C) solution of picolinoyl chloride (5.0 mmol, 1.0 eq) and fluoroacetonitrile (278 μί, 5.0

1337 mmol, 1.0 eq) in dry THF (15 mL) was added a solution of LHMDS in THF (1 M, 10 mL,

1338 10.0 mmol, 2.0 eq). The mixture was allowed to reach room temperature, and IN HC1 was

1339 added dropwise achieving pH 2. The mixture was concentrated under reduced pressure to

1340 afford intermediate 2 in a form pure enough for the next step.

1341 Example 3 - Preparation of Intermediate 3

1343 Intermediate 3

1344 [0161] General Procedure 1 was followed to obtain Intermediate 3. Thus, to a cold (-78

1345 °C) solution of pyran-4-carbonyl chloride (5.0 mmol, 1.0 eq) and fluoroacetonitrile (278 μί,

1346 5.0 mmol, 1.0 eq) in dry THF (15 mL) was added a solution of LHMDS in THF (1 M, 10

1347 mL, 10.0 mmol, 2.0 eq). The mixture was allowed to reach room temperature, and IN HC1 1348 was added dropwise achieving pH 2. The mixture was concentrated under reduced pressure

1349 to afford intermediate 3 in a form pure enough for the next step.

1350 Example 4 - Preparation of Intermediate 4

1351 [0162] The synthesis of Intermediate 4 followed the procedure of General Procedure 2

1352 following.

1353 General Procedure 2

1355 Intermediate 1 Intermediate 4

1356 [0163] To a solution of intermediate 1 (5.0 mmol) in ethanol (15 mL) was added hydrazine

1357 monohydrate (582 μί, 12.0 mmol, 2.4 eq). The reaction was heated at reflux for 18 h. The

1358 reaction mixture was allowed to cool to room temperature, and the solvent was evaporated

1359 under reduced pressure. The residue was dissolved in dichloromethane (DCM) and washed

1360 with water. The organic phase was concentrated to give a crude product that was purified by

1361 silica column, yielding intermediate 4 as a light brown solid (0.56 g, 55%). Ή NMR (400

1362 MHz, DMSO-d₆) δ (ppm): 4.80 (s, 2H), 7.28-7.32 (m, 1H), 7.41-7.45 (m, 2H), 7.62-7.64 (m,

1363 2H), 1 1 .88 (s, 1 H).

1364 Example 5 - Preparation of Intermediate 5

1

366 Intermediate 2

1367 [0164] General Procedure 2 was followed to convert Intermediate 2 to Intermediate 5 1368

1369 Example 6 - Preparation of Intermediate 6

_{1 370}

1371 Intermediate 3 Intermediate 6

1372 [0165] General Procedure 2 was followed to convert Intermediate 3 to Intermediate 6 1373 Example 7 - Preparation of Intermediate 7

1374 [0166] The synthesis of Intermediate 7 followed the procedure of General Procedure 3

1375 following.

1376 General Procedure 3

_{1 377}

1378 Intermediate 4 Intermediate 7

1379 [0167] A solution of intermediate 4 (12.4 mmol) and benzaldehyde (24.8 mmol, 2 eq) in

1380 EtOH (20 mL) with molecular sieves (4A powder) was refluxed for 8 h. Then was added a

1381 catalytic quantity of AcOH, NaCNBH₃ (1.6 g, 24.8 mmol, 2 eq) at 0 °C with stirring for 15 h

1382 at RT. The solvent was distilled off, and the residue was dissolved in EtOAc (200 mL) and

1383 filtered through a Celite® pad to remove inorganic materials. The filtrate was washed with

1384 saturated aqueous NaHC0₃ (2 ^χ 20 mL), water (20 mL), brine (20 mL), dried over Na₂S0₄,

1385 filtered and concentrated in vacuo. The resultant compound was purified by column

1386 chromatography over silica gel (100-200 mesh) by using a solvent gradient of 0-10% MeOH-

1387 CHCI3 as the eluent to afford Intermediate 7.

1388 Example 8 - Preparation of Intermediate 8

1390 Intermediate 4 Intermediate s

1391 [0168] General Procedure 3 was followed to convert Intermediate 4 to Intermediate 8

1392 Example 9 - Preparation of Compound 23

1393 [0169] The synthesis of Compound 23 followed the procedure of General Procedure 4

1394 following.

1395 396 General Procedure 4

1398 Intermediate 7 Compound 23

1399 [0170] Pivaloyl chloride was added to a solution of Intermediate 7 in triethylamine (3 mL)

1400 at RT and stirred for 5 h. The reaction mixture was diluted with water (5 mL) and extracted

1401 with EtOAc (20 mL). The organic layer washed with water (2 >< 5 mL), saturated aqueous

1402 NaHCC>3 (5 mL), brine (5 mL), dried over Na₂S0₄, filtered and concentrated in vacuo. The

1403 crude compound was purified by column chromatography over silica gel (100-200 mesh) by

1404 using a gradient mixture of 0-30% EtOAc-hexane as the eluent to afford Compound 23

1405 (33%). MP 105-106°C; Ή NMR: (DMSO-d₆) δ 7.77 (d, J = 7.4 Hz, 2H), 7.56-7.60 (m, 1H),

1406 7.41 -7.52 (m, 3H), 7.33-7.38 (m, 4H), 7.25 (br s, I H), 4.53 (d, J = 6.2 Hz, 2H), 1.48 (s, 9H);

1407 MS: 352 [M + H]⁺.

1408 Example 10 - Preparation of Compound 10

1409

1410 Intermediate 8 Compound 10

141 1 [0171] General Procedure 4 was followed to convert Intermediate 8 to Compound 10.

1412 Thus, pivaloyl chloride was added to a solution of Intermediate 8 in triethylamine (3 mL) at

1413 RT and stirred for 5 h. The reaction mixture was diluted with water (5 mL) and extracted with

1414 EtOAc (20 mL). The organic layer washed with water (2 x 5 mL), saturated aqueous

1415 NaHC0₃ (5 mL), brine (5 mL), dried over Na₂S0₄, filtered and concentrated in vacuo. The

1416 crude compound was purified by column chromatography over silica gel (100-200 mesh) by

1417 using a gradient mixture of 0-30% EtOAc-hexane as the eluent to afford Compound 10

1418 (35%). 'H NMR: (CDC1₃) δ 7.8-7.9 (m, 2H), 7.40-7.48 (m, 3H), 7.10-7.18 (m, 1H), 6.74-

1419 6.81 (m, 2H), 4.63 (d, J = 6.2 Hz, 2H), 1.53 (s, 9H); MS: 392 [M + H]⁺. 1420 ? 11 - Preparation of Intermediate

1422 Intermediate 6 Intermediate 9

1423 [0172] General Procedure 3 was followed to convert Intermediate 6 to Intermediate 9

1424 Example 12 - Preparation of Compound 3

1426 Intermediate 9 Compound 3

1427 [0173] General Procedure 4 was followed to convert Intermediate 9 to Compound 3. 1428 Thus, pivaloyl chloride was added to a solution of Intermediate 9 in triethylamine (3 mL) at 1429 RT and stirred for 5 h. The reaction mixture was diluted with water (5 mL) and extracted with 1430 EtOAc (20 mL). The organic layer washed with water (2 >< 5 mL), saturated aqueous 1431 NaHCC"3 (5 mL), brine (5 mL), dried over Na₂S04, filtered and concentrated in vacuo. The 1432 crude compound was purified by column chromatography over silica gel (100-200 mesh) by 1433 using a gradient mixture of 0-30% EtOAc-hexane as the eluent to afford Compound 3 (46%). 1434 Ή NMR: (CDCb) δ 7.03 (t, J = 7.0 Hz, 1H), 6.75 (br s, 2H), 4.54 (d, J = 6.2 Hz, 2H), 4.01 - 1435 4.06 (m, 2H), 3.50 - 3.57 (m, 2H), 2.89 - 2.93 (m, 1H), 1.87 - 1.91 (m, 4H), 1.44 (s, 9H); 1436 MS: 400 [M + H]⁺.

Exam le 13 - Preparation of Intermediate 10

1

439 Intermediate 5

[0174] General Procedure 3 was followed to convert Intermediate 5 to Intermediate 10 - Preparation of Compound 22

1443 Intermediate 10 Compound 22

1444 [0175] General Procedure 4 was followed to convert Intermediate 10 to Compound 22.

1445 Thus, pivaloyl chloride was added to a solution of Intermediate 10 in triethylamine (3 mL) at

1446 RT and stirred for 5 h. The reaction mixture was diluted with water (5 mL) and extracted with

1447 EtOAc (20 mL). The organic layer washed with water (2 >< 5 mL), saturated aqueous

1448 NaHC(¾ (5 mL), brine (5 mL), dried over Na₂S0₄, filtered and concentrated in vacuo. The

1449 crude compound was purified by column chromatography over silica gel (100-200 mesh) by

1450 using a gradient mixture of 0-30% EtOAc-hexane as the eluent to afford Compound 22

1451 (40%). Ή NMR: (DMSO-d₆) δ 8.6 (m, 1 H), 7.83 - 7.91 (m, 2H), 7.55 (m, 1 H), 7.25 - 7.45

1452 (m, 6H), 4.52 - 4.54 (m, 2H), 1.48 (s, 9H); MS: 353.03 [M + H]⁺.

1453

1454 [0176] The contents of all references, patents, and published applications cited herein are

1455 hereby incorporated by reference in their entirety and for all purposes.

1456 [0177] While the invention has been described in detail with reference to certain preferred

1457 embodiments thereof, it will be understood that modifications and variations are within the

1458 spirit and scope of that which is described and claimed.

Claims

WHAT IS CLAIMED IS:

1460 1. A compound with structure of Formula (la):

1462 or pharmaceutically acceptable salt, ester, solvate, or prodrug thereof;

1463 wherein

1464 Ring A is substituted or unsubstituted pyrazolyl;

1465 L¹ and L³ are independently a bond, substituted or unsubstituted alkylene, substituted

1466 or unsubstituted heteroalkylene, -S-, -SO-, -S0₂-, -0-, -NHS0₂-, or -NR⁴-;

1467 L² is absent, a bond, substituted or unsubstituted alkylene, substituted or unsubstituted

1468 heteroalkylene, -S-, -SO-, -S0₂-, -0-, -NHS0₂-, or -NR⁴-;

1469 R¹ and R³ are independently hydrogen, halogen, substituted or unsubstituted alkyl,

1470 substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or

1471 unsubstituted cycloalkenyl, substituted or unsubstituted heterocycloalkyl, substituted or

1472 unsubstituted heterocycloalkenyl, substituted or unsubstituted aryl, substituted or

1473 unsubstituted fused ring aryl, or substituted or unsubstituted heteroaryl;

1474 R² is absent, hydrogen, halogen, substituted or unsubstituted alkyl, substituted or

1475 unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted

1476 cycloalkenyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted

1477 heterocycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted fused ring

2 2

1478 aryl, or substituted or unsubstituted heteroaryl, provided that when L is absent, R is absent;

1479 R⁴ is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted

1480 heteroalkyl, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene,

1481 substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl,

1482 substituted or unsubstituted aryl, substituted or unsubstituted cycloalkenyl, substituted or

1483 unsubstituted heterocycloalkenyl, and substituted or unsubstituted fused ring aryl or

1484 substituted or unsubstituted heteroaryl; and

1485 Y is a halogen.

1486 2. The compound according to claim 1, wherein L² and R² are absent.

1487 3. The compound according to claim 1 , with structure of Formula (Ila) or

1488 Formula (lib):

1490 4. The compound according to claim 3, with structure of Formula (Ila), wherein

1491 L³ is a bond, or substituted or unsubstituted alkylene, and R³ is substituted or unsubstituted

1492 aryl, substituted or unsubstituted fused ring aryl, substituted or unsubstituted

1493 heterocycloalkyl, or substituted or unsubstituted heteroaryl, and Y is fluorine.

1494 5. The compound according to claim 3, with structure of Formula (Ila), wherein

1495 L³ is -C(0)0-, R³ is substituted or unsubstituted alkyl, and Y is fluorine.

1496 6. The compound according to claim 3, with structure of Formula (Ila), wherein

1497 L³ is -C(0)NR⁵-, R⁵ is hydrogen or alkyl, R³ is substituted or unsubstituted alkyl, or

1498 substituted or unsubstituted aryl, and Y is fluorine.

1499 7. The compound according to claim 4, wherein R³ is substituted or unsubstituted

1500 phenyl.

1501 8. The compound according to claim 4, wherein said heteroaryl is pyridyl,

1502 pyridazinyl, pyrimidinyl, thienyl, or furyl.

1503 9. The compound according to claim 8, wherein R³ is chloro-substituted thienyl.

1504 10. The compound according to claim 4, wherein said heterocycloalkyl is

1505 morpholinyl, oxanyl, or oxetanyl.

1506 1 1. The compound according to claim 4, wherein said fused ring aryl is

1507 benzodioxinyl or naphthyl.

1508 12. The compound according to any of claims 4 to 1 1 , wherein L¹ is a bond, -S-,

1509 -NR⁴-, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene,

1510 and R¹ is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl,

151 1 substituted or unsubstituted fused ring aryl, substituted or unsubstituted heteroaryl, or

1512 substituted or unsubstituted heterocycloalkyl.

1513 13. The compound according to claim 12, wherein said heteroaryl is pyridyl,

1514 pyridazinyl, pyrimidinyl, thienyl, or furyl.

1515 14. The compound according to claim 13, wherein R¹ is chloro-substituted thienyl.

1516 15. The compound according to claim 12, wherein said heterocycloalkyl is

151 7 morpholiny 1, oxanyl, or oxetany 1.

1518 16. The compound according to claim 12, wherein said fused ring aryl is

1519 benzodioxinyl or naphthyl.

1520 17. The compound according to claim 12, wherein R¹ is substituted or

1521 unsubstituted phenyl.

2 2 ·

1522 1 8. The compound according to claim 4, wherein L is a bond, and R is

1523 hydrogen.

1524 19. The compound according to claim 4, wherein L² is substituted or unsubstituted

1525 alkylene or -C(O)-, and R² is hydrogen, substituted or unsubstituted alkyl, substituted or

1526 unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted

1527 cycloalkenyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted

1528 heterocycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted fused ring

1529 aryl, or substituted or unsubstituted heteroaryl.

1530 20. The compound according to claim 19, wherein said heteroaryl is pyridyl,

1531 pyridazinyl, pyrimidinyl, thienyl, or furyl.

1532 21. The compound according to claim 19, wherein R² is substituted or

1533 unsubstituted alkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted

1534 heterocycloalkyl.

1535 22. The compound according to claim 21 , wherein said heterocycloalkyl is

1536 morpholinyl, oxanyl, or oxetanyl.

1537 23. The compound according to claim 19, wherein said fused ring aryl is

1538 benzodioxinyl or naphthyl.

1539 24. The compound according to claim 19, wherein R² is substituted or

1540 unsubstituted phenyl.

1541 25. The compound according to claim 3, with structure of Formula (lib), wherein

1542 L³ is a bond, or substituted or unsubstituted alkylene, R³ is substituted or unsubstituted aryl,

1543 substituted or unsubstituted fused ring aryl, substituted or unsubstituted heterocycloalkyl, or

1544 substituted or unsubstituted heteroaryl, and Y is fluorine.

1545 26. The compound according to claim 3, with structure of Formula (lib), wherein

1546 L³ is -C(0)0, R³ is substituted or unsubstituted alkyl, and Y is fluorine.

1547 27. The compound according to claim 3, with structure of Formula (lib), wherein

1548 L³ is -C(0)NR⁵-, R⁵ is hydrogen or alkyl, R³ is substituted or unsubstituted alkyl, or

1549 substituted or unsubstituted aryl, and Y is fluorine.

1550 28. The compound according to claim 25, wherein R³ is substituted or

1551 unsubstituted phenyl.

1552 29. The compound according to claim 25, wherein said heteroaryl is pyridyl,

1553 pyridazinyl, pyrimidinyl, thienyl, or furyl.

1554 30. The compound according to claim 29, wherein R³ is chloro-substituted thienyl.

1555 31. The compound according to claim 25, wherein said heterocycloalkyl is

1556 morpholinyl, oxanyl, or oxetanyl.

1557 32. The compound according to claim 25, wherein said fused ring aryl is

1558 benzodioxinyl or naphthyl.

1559 33. The compound according to any of claims 25 to 32, wherein L¹ is a bond, -S-,

1560 -NR⁴-, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene,

1561 and R¹ is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl,

1562 substituted or unsubstituted fused ring aryl, substituted or unsubstituted heteroaryl, or

1563 substituted or unsubstituted heterocycloalkyl.

1564 34. The compound according to claim 33, wherein said heteroaryl is pyridyl,

1565 pyridazinyl, pyrimidinyl, thienyl, or furyl.

1566 35. The compound according to claim 34, wherein R¹ is chloro-substituted thienyl.

1567 36. The compound according to claim 33, wherein said heterocycloalkyl is

1568 morpholinyl, oxanyl, or oxetanyl.

1569 37. The compound according to claim 33, wherein said fused ring aryl is

1570 benzodioxinyl or naphthyl.

1571 38. The compound according to claim 33, wherein R¹ is substituted or

1572 unsubstituted phenyl.

2 2 ·

1573 39. The compound according to claim 25, wherein L is a bond, and R is

1574 hydrogen.

1575 40. The compound according to claim 25, wherein L² is substituted or

1576 unsubstituted alkylene or -C(O)-, and R² is hydrogen, substituted or unsubstituted alkyl,

1577 substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or

1578 unsubstituted cycloalkenyl, substituted or unsubstituted heterocycloalkyl, substituted or

1579 unsubstituted heterocycloalkenyl, substituted or unsubstituted aryl, substituted or

1580 unsubstituted fused ring aryl, or substituted or unsubstituted heteroaryl.

1581 41. The compound according to claim 40, wherein said heteroaryl is pyridyl,

1582 pyridazinyl, pyrimidinyl, thienyl, or furyl.

1 583 42. The compound according to claim 40, wherein R² is substituted or

1584 unsubstituted alkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted

1 585 heterocycloalkyl.

1 586 43. The compound according to claim 42, wherein said heterocycloalkyl is

1 587 morpholinyl, oxanyl, or oxetanyl.

1 588 44. The compound according to claim 40, wherein said fused ring aryl is

1589 benzodioxinyl or naphthyl.

1 590 45. The compound according to claim 40, wherein R² is substituted or

1 591 unsubstituted phenyl.

1 592 46. The compound according to any of claims 1 to 45 as set forth in Table A.

1 593 47. A pharmaceutical composition comprising a compound according to any of

1594 claims 1 to 45, or a compound as set forth in Table A, and a pharmaceutically acceptable

1 595 excipient.

1596 48. A method for treating a disease or disorder in a subject, comprising

1 597 administering a compound according to any of claims 1 to 46 or a pharmaceutical

1598 composition according to claim 47, to a subject in need thereof in an amount effective to treat

1 599 said disease or disorder.

1600 49. The method according to claim 48, wherein said disease or disorder is a

1601 thrombotic disorder.

1602 50. The method according to claim 49, wherein said thrombotic disorder is acute

1603 coronary syndrome, venous thromboembolism, arterial thromboembolism or cardiogenic

1604 thromboembolism.

1605 51. The method according to claim 48, wherein said disease or disorder is fibrosis.

1606 52. The method according to claim 48, wherein said disease or disorder is

1607 Alzheimer's Disease.

1608 53. The method according to claim 48, wherein said disease or disorder is multiple

1609 sclerosis.

1610 54. The method according to claim 48, wherein said disease or disorder is pain.

1 61 1 55. The method according to claim 48, wherein said disease or disorder is cancer.

1612 56. A method for preventing a disease or disorder in a subject, comprising

1613 administering a compound according to any of claims 1 to 46 or a pharmaceutical

1614 composition according to claim 47, to a subject in need thereof in an amount effective to

1615 prevent said disease or disorder.

1616 57. The method according to claim 56, wherein said disease or disorder is a

1617 thrombotic disorder.

1618 58. The method according to claim 56, wherein said thrombotic disorder is acute

1619 coronary syndrome, venous thromboembolism, arterial thromboembolism or cardiogenic

1620 thromboembolism.

1621 59. The method according to claim 56, wherein said thrombotic disorder is

1622 disseminated intravascular coagulation.

1623 60. The method according to claim 56, wherein said thrombotic disorder involves

1624 the presence or the potential formation of a blood clot thrombus.